One	O
gene	O
,	O
two	O
transcripts	B-RNA
:	O
isolation	O
of	O
an	O
alternative	O
transcript	O
encoding	O
for	O
the	O
autoantigen	B-protein
La/SS-B	I-protein
from	O
a	O
cDNA	B-DNA
library	I-DNA
of	O
a	O
patient	O
with	O
primary	O
Sjogrens	O
'	O
syndrome	O
.	O

A	O
cDNA	B-DNA
library	I-DNA
was	O
prepared	O
from	O
peripheral	O
blood	O
lymphocytes	B-cell_type
of	O
an	O
autoimmune	O
patient	O
with	O
primary	O
Sjogrens	O
'	O
syndrome	O
.	O

The	O
cDNA	B-DNA
library	I-DNA
was	O
screened	O
with	O
the	O
patients	O
own	O
autoimmune	O
serum	O
being	O
monospecific	O
for	O
the	O
nuclear	B-protein
autoantigen	I-protein
La/SS-B	I-protein
.	O

Thereby	O
an	O
alternative	O
type	O
of	O
La	B-RNA
mRNA	I-RNA
was	O
identified	O
that	O
differed	O
from	O
the	O
known	O
La	B-RNA
mRNA	I-RNA
due	O
to	O
an	O
exchange	O
of	O
the	O
exon	B-DNA
1	I-DNA
.	O

Sequencing	O
of	O
the	O
genomic	O
region	O
between	O
the	O
exons	B-DNA
1	I-DNA
and	I-DNA
2	I-DNA
showed	O
that	O
the	O
alternative	B-DNA
5'-end	I-DNA
is	O
a	O
part	O
of	O
the	O
intron	B-DNA
.	O

In	O
addition	O
,	O
the	O
presence	O
of	O
an	O
alternative	B-DNA
promoter	I-DNA
site	I-DNA
,	O
which	O
exists	O
within	O
the	O
intron	B-DNA
downstream	O
of	O
the	O
exon	B-DNA
1	I-DNA
,	O
became	O
evident	O
.	O

In	O
consequence	O
,	O
the	O
alternative	B-RNA
La	I-RNA
mRNA	I-RNA
is	O
the	O
result	O
of	O
a	O
promoter	O
switching	O
combined	O
with	O
an	O
alternative	O
splicing	O
mechanism	O
.	O

In	O
the	O
intron	O
,	O
further	O
transcription	B-protein
factor	I-protein
binding	O
sites	O
,	O
including	O
a	O
NF-kappa	B-DNA
B	I-DNA
element	I-DNA
,	O
were	O
identified	O
leading	O
to	O
the	O
suggestion	O
that	O
the	O
expression	O
of	O
the	O
gene	O
encoding	O
for	O
the	O
nuclear	B-protein
autoantigen	I-protein
La/SS-B	I-protein
alters	O
in	O
dependence	O
on	O
disease	O
conditions	O
.	O

One	NULL
Gene	NULL
,	NULL
Two	NULL
Transcripts	NULL
:	NULL
Isolation	NULL
of	NULL
an	NULL
Alternative	NULL
Transcript	NULL
Encoding	NULL
for	NULL
the	NULL
Autoantigen	NULL
La/SS-B	NULL
from	NULL
a	NULL
cDNA	NULL
Library	NULL
of	NULL
a	NULL
Patient	NULL
with	NULL
Primary	NULL
Sjogrens	NULL
'	NULL
Syndrome	NULL
By	NULL
Helmut	NULL
Troster	NULL
,	NULL
``	NULL
Thomas	NULL
E.	NULL
Metzger	NULL
,	NULL
``	NULL
Imre	NULL
Semsei	NULL
,	NULL
*	NULL
Martin	NULL
Schwemmle	NULL
,	NULL
§	NULL
Andreas	NULL
Winterpacht	NULL
,	NULL
?	NULL

Bernhard	NULL
Zabel	NULL
,	NULL
?	NULL

and	NULL
Michael	NULL
Bachmann*	NULL
From	NULL
the	NULL
Institute	NULL
fiir	NULL
*Physiologische	NULL
Chemie	NULL
and	NULL
'Paediatrie	NULL
,	NULL
Johannes-	NULL
Gutenberg	NULL
Universitit	NULL
,	NULL
D-55099	NULL
Mainz	NULL
;	NULL
and	NULL
Sthe	NULL
Institute	NULL
fiir	NULL
Virologie	NULL
,	NULL
Albert-Ludwigs-	NULL
Universitit	NULL
Freiburg	NULL
,	NULL
D-79104	NULL
Freiburg	NULL
,	NULL
Germany	NULL
Summary	NULL
A	NULL
cDNA	NULL
library	NULL
was	NULL
prepared	NULL
from	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
of	NULL
an	NULL
autoimmune	NULL
patient	NULL
with	NULL
primary	NULL
Sjogrens	NULL
'	NULL
syndrome	NULL
.	NULL

The	NULL
cDNA	NULL
library	NULL
was	NULL
screened	NULL
with	NULL
the	NULL
patients	NULL
own	NULL
autoimmune	NULL
serum	NULL
being	NULL
monospecific	NULL
for	NULL
the	NULL
nuclear	NULL
autoantigen	NULL
La/SS-B	NULL
.	NULL

Thereby	NULL
an	NULL
alternative	NULL
type	NULL
of	NULL
La	NULL
mRNA	NULL
was	NULL
identified	NULL
that	NULL
differed	NULL
from	NULL
the	NULL
known	NULL
La	NULL
mRNA	NULL
due	NULL
to	NULL
an	NULL
exchange	NULL
of	NULL
the	NULL
exon	NULL
1	NULL
.	NULL

Sequencing	NULL
of	NULL
the	NULL
genomic	NULL
region	NULL
between	NULL
the	NULL
exons	NULL
1	NULL
and	NULL
2	NULL
showed	NULL
that	NULL
the	NULL
alternative	NULL
5-end	NULL
is	NULL
a	NULL
part	NULL
of	NULL
the	NULL
intron	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
presence	NULL
of	NULL
an	NULL
alternative	NULL
promoter	NULL
site	NULL
,	NULL
which	NULL
exists	NULL
within	NULL
the	NULL
intron	NULL
downstream	NULL
of	NULL
the	NULL
exon	NULL
1	NULL
,	NULL
became	NULL
evident	NULL
.	NULL

In	NULL
consequence	NULL
,	NULL
the	NULL
alternative	NULL
La	NULL
mRNA	NULL
is	NULL
the	NULL
result	NULL
of	NULL
a	NULL
promoter	NULL
switching	NULL
combined	NULL
with	NULL
an	NULL
alternative	NULL
splicing	NULL
mechanism	NULL
.	NULL

In	NULL
the	NULL
intron	NULL
,	NULL
further	NULL
transcription	NULL
factor	NULL
binding	NULL
sites	NULL
,	NULL
including	NULL
a	NULL
NF-KB	NULL
element	NULL
,	NULL
were	NULL
identified	NULL
leading	NULL
to	NULL
the	NULL
suggestion	NULL
that	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
gene	NULL
encoding	NULL
for	NULL
the	NULL
nuclear	NULL
autoantigen	NULL
La/SS-B	NULL
alters	NULL
in	NULL
dependence	NULL
on	NULL
disease	NULL
conditions	NULL
.	NULL

he	NULL
basic	NULL
mechanisms	NULL
for	NULL
development	NULL
of	NULL
autoimmunity	NULL
,	NULL
including	NULL
the	NULL
development	NULL
of	NULL
autoantibodies	NULL
directed	NULL
to	NULL
nuclear	NULL
antigens	NULL
(	NULL
ANAs	NULL
)	NULL
'	NULL
,	NULL
in	NULL
patients	NULL
with	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
(	NULL
SLE	NULL
)	NULL
or	NULL
primary	NULL
Sjégrens	NULL
'	NULL
syndrome	NULL
(	NULL
pSS	NULL
)	NULL
are	NULL
not	NULL
understood	NULL
.	NULL

It	NULL
is	NULL
assumed	NULL
that	NULL
unknown	NULL
genomic	NULL
prerequisites	NULL
together	NULL
with	NULL
viruses	NULL
may	NULL
play	NULL
a	NULL
role	NULL
during	NULL
development	NULL
of	NULL
autoimmunity	NULL
.	NULL

Especially	NULL
herpesviruses	NULL
,	NULL
including	NULL
the	NULL
Epstein	NULL
Barr	NULL
virus	NULL
as	NULL
well	NULL
as	NULL
exogenous	NULL
or	NULL
en-dogenous	NULL
retroviruses	NULL
,	NULL
were	NULL
discussed	NULL
as	NULL
possible	NULL
causative	NULL
agents	NULL
of	NULL
these	NULL
diseases	NULL
(	NULL
1	NULL
,	NULL
2	NULL
)	NULL
.	NULL

An	NULL
involvement	NULL
of	NULL
retroviruses	NULL
in	NULL
pSS	NULL
is	NULL
supported	NULL
by	NULL
(	NULL
a	NULL
)	NULL
an	NULL
appearance	NULL
of	NULL
antibodies	NULL
to	NULL
retroviral	NULL
proteins	NULL
in	NULL
patients	NULL
with	NULL
pSS	NULL
and	NULL
(	NULL
b	NULL
)	NULL
the	NULL
isolation	NULL
of	NULL
an	NULL
A-type	NULL
retroviral	NULL
particle	NULL
in	NULL
lymphoblastoid	NULL
cells	NULL
exposed	NULL
to	NULL
homogenates	NULL
of	NULL
salivary	NULL
tissue	NULL
from	NULL
patients	NULL
with	NULL
pSS	NULL
(	NULL
3	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
(	NULL
HIV	NULL
)	NULL
,	NULL
can	NULL
produce	NULL
a	NULL
clinical	NULL
syndrome	NULL
and	NULL
immunologic	NULL
changes	NULL
similar	NULL
to	NULL
those	NULL
seen	NULL
in	NULL
pSS	NULL
,	NULL
including	NULL
the	NULL
development	NULL
of	NULL
ANAs	NULL
(	NULL
4	NULL
)	NULL
.	NULL

Nonetheless	NULL
,	NULL
even	NULL
if	NULL
these	NULL
or	NULL
other	NULL
viruses	NULL
are	NULL
involved	NULL
in	NULL
autoimmunity	NULL
in	NULL
pSS	NULL
and	NULL
SLE	NULL
patients	NULL
,	NULL
the	NULL
mechanism	NULL
by	NULL
which	NULL
viruses	NULL
can	NULL
lead	NULL
to	NULL
the	NULL
development	NULL
1	NULL
Abbreviations	NULL
used	NULL
in	NULL
this	NULL
paper	NULL
:	NULL
ANA	NULL
,	NULL
autoantibodies	NULL
directed	NULL
to	NULL
nuclear	NULL
antigen	NULL
;	NULL
pSS	NULL
,	NULL
primary	NULL
Sjogrens	NULL
'	NULL
syndrome	NULL
;	NULL
SLE	NULL
,	NULL
systemic	NULL
lupus	NULL
erythem-atosus	NULL
.	NULL

of	NULL
ANAs	NULL
remains	NULL
obscure	NULL
,	NULL
as	NULL
these	NULL
autoantibodies	NULL
are	NULL
at	NULL
least	NULL
partially	NULL
the	NULL
product	NULL
of	NULL
an	NULL
autoantigen	NULL
driven	NULL
oligoclonal	NULL
B	NULL
cell	NULL
response	NULL
(	NULL
5	NULL
,	NULL
6	NULL
)	NULL
.	NULL

One	NULL
of	NULL
the	NULL
targets	NULL
of	NULL
an	NULL
ANA	NULL
system	NULL
is	NULL
the	NULL
nuclear	NULL
autoantigen	NULL
La/SS-B	NULL
(	NULL
7	NULL
)	NULL
.	NULL

La	NULL
protein	NULL
has	NULL
been	NULL
suggested	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
transcription	NULL
termination	NULL
of	NULL
RNA	NULL
polymerase	NULL
III	NULL
and	NULL
internal	NULL
initiation	NULL
of	NULL
translation	NULL
of	NULL
at	NULL
least	NULL
poliovirus	NULL
mRNA	NULL
(	NULL
8-10	NULL
)	NULL
.	NULL

Up	NULL
to	NULL
now	NULL
more	NULL
than	NULL
20	NULL
La	NULL
cDNAs	NULL
have	NULL
been	NULL
isolated	NULL
by	NULL
six	NULL
independent	NULL
groups	NULL
and	NULL
no	NULL
dramatic	NULL
differences	NULL
had	NULL
been	NULL
observed	NULL
(	NULL
11-16	NULL
)	NULL
.	NULL

The	NULL
transcription	NULL
of	NULL
this	NULL
described	NULL
type	NULL
of	NULL
La	NULL
mRNA	NULL
was	NULL
suggested	NULL
to	NULL
occur	NULL
from	NULL
a	NULL
GC-rich	NULL
promotor	NULL
region	NULL
upstream	NULL
of	NULL
the	NULL
exon	NULL
1	NULL
lacking	NULL
a	NULL
TATA-element	NULL
,	NULL
leading	NULL
to	NULL
the	NULL
conclusion	NULL
that	NULL
La	NULL
protein	NULL
belongs	NULL
to	NULL
the	NULL
housekeeping	NULL
proteins	NULL
(	NULL
17	NULL
)	NULL
.	NULL

In	NULL
case	NULL
of	NULL
some	NULL
protooncogenes	NULL
,	NULL
inflammatory	NULL
mediators	NULL
,	NULL
signal	NULL
transduction	NULL
components	NULL
,	NULL
proteins	NULL
involved	NULL
in	NULL
the	NULL
immune	NULL
response	NULL
,	NULL
transcription	NULL
factors	NULL
,	NULL
growth	NULL
factor	NULL
receptors	NULL
,	NULL
and	NULL
some	NULL
other	NULL
housekeeping	NULL
proteins	NULL
,	NULL
in	NULL
addition	NULL
to	NULL
the	NULL
respective	NULL
translatable	NULL
mRNA	NULL
,	NULL
an	NULL
alternative	NULL
mRNA	NULL
has	NULL
been	NULL
described	NULL
.	NULL

Usually	NULL
the	NULL
exon	NULL
1	NULL
is	NULL
replaced	NULL
in	NULL
the	NULL
respective	NULL
alternative	NULL
mRNA	NULL
.	NULL

The	NULL
alternative	NULL
5'-terminus	NULL
alters	NULL
the	NULL
properties	NULL
of	NULL
the	NULL
mRNAs	NULL
dramatically	NULL
as	NULL
it	NULL
contains	NULL
GC-rich	NULL
regions	NULL
and/or	NULL
additional	NULL
less	NULL
functional	NULL
AUGs	NULL
upstream	NULL
of	NULL
the	NULL
major	NULL
open	NULL
reading	NULL
frame	NULL
(	NULL
18	NULL
)	NULL
.	NULL

Due	NULL
to	NULL
their	NULL
unusual	NULL
5'-terminal	NULL
structure	NULL
,	NULL
such	NULL
mRNAs	NULL
were	NULL
hypothesized	NULL
to	NULL
ei-	NULL
2059	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

©	NULL
The	NULL
Rockefeller	NULL
University	NULL
Press	NULL
+	NULL
0022-1007/94/12/2059/09	NULL
$	NULL
2.00	NULL
Volume	NULL
180	NULL
December	NULL
1994	NULL
2059-2067	NULL
ther	NULL
throttle	NULL
the	NULL
translation	NULL
of	NULL
the	NULL
functional	NULL
counterpart	NULL
or	NULL
represent	NULL
intermediates	NULL
that	NULL
can	NULL
be	NULL
further	NULL
processed	NULL
depending	NULL
on	NULL
the	NULL
tissue	NULL
(	NULL
18	NULL
)	NULL
.	NULL

Here	NULL
we	NULL
describe	NULL
the	NULL
isolation	NULL
and	NULL
characterization	NULL
of	NULL
such	NULL
an	NULL
alternative	NULL
type	NULL
of	NULL
mRNA	NULL
derived	NULL
from	NULL
the	NULL
gene	NULL
encoding	NULL
for	NULL
the	NULL
autoantigen	NULL
La/SS-B	NULL
.	NULL

Materials	NULL
and	NULL
Methods	NULL
Preparation	NULL
of	NULL
a	NULL
cDNA	NULL
Library	NULL
from	NULL
the	NULL
PBL	NULL
of	NULL
a	NULL
Patient	NULL
with	NULL
pSS	NULL
.	NULL

RNA	NULL
was	NULL
isolated	NULL
from	NULL
PBL	NULL
of	NULL
a	NULL
patient	NULL
with	NULL
pSS	NULL
(	NULL
Ma	NULL
)	NULL
as	NULL
basically	NULL
described	NULL
by	NULL
Chirgwin	NULL
et	NULL
al	NULL
.	NULL

(	NULL
19	NULL
)	NULL
using	NULL
modifications	NULL
according	NULL
to	NULL
Semsei	NULL
and	NULL
Cutler	NULL
(	NULL
20	NULL
)	NULL
.	NULL

Poly	NULL
(	NULL
A	NULL
)	NULL
*	NULL
mRNA	NULL
was	NULL
isolated	NULL
from	NULL
the	NULL
RNA	NULL
preparation	NULL
using	NULL
oligo	NULL
(	NULL
dT	NULL
)	NULL
-column	NULL
chroma-tography	NULL
(	NULL
20	NULL
)	NULL
.	NULL

The	NULL
cDNAs	NULL
were	NULL
synthesized	NULL
using	NULL
the	NULL
ZAP-cDNA	NULL
synthesis	NULL
kit	NULL
and	NULL
ligated	NULL
to	NULL
the	NULL
Uni-ZAPXR	NULL
vector	NULL
arms	NULL
(	NULL
Stratagene	NULL
,	NULL
Heidelberg	NULL
,	NULL
Germany	NULL
,	NULL
21	NULL
)	NULL
.	NULL

The	NULL
A-library	NULL
was	NULL
packaged	NULL
by	NULL
Giga-pack	NULL
II	NULL
Gold	NULL
packaging	NULL
extract	NULL
(	NULL
Stratagene	NULL
)	NULL
,	NULL
plated	NULL
and	NULL
amplified	NULL
in	NULL
the	NULL
Escherichia	NULL
coli	NULL
cell	NULL
lines	NULL
PKL-F	NULL
'	NULL
and	NULL
XL1-Blue	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
complexity	NULL
of	NULL
the	NULL
library	NULL
was	NULL
10°	NULL
pfu	NULL
.	NULL

Immunoscreening	NULL
.	NULL

-	NULL
Immunoscreening	NULL
was	NULL
performed	NULL
using	NULL
the	NULL
patient	NULL
's	NULL
anti-La	NULL
serum	NULL
(	NULL
10	NULL
ml	NULL
)	NULL
.	NULL

Before	NULL
use	NULL
,	NULL
the	NULL
serum	NULL
was	NULL
extensively	NULL
preadsorbed	NULL
to	NULL
a	NULL
Sepharose	NULL
4B	NULL
column	NULL
(	NULL
5	NULL
ml	NULL
)	NULL
,	NULL
which	NULL
had	NULL
been	NULL
covalently	NULL
linked	NULL
to	NULL
a	NULL
total	NULL
extract	NULL
obtained	NULL
from	NULL
E.	NULL
coli	NULL
(	NULL
strain	NULL
Y¥1090	NULL
)	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
10	NULL
mg/ml	NULL
gel	NULL
.	NULL

The	NULL
first	NULL
screening	NULL
was	NULL
followed	NULL
by	NULL
second	NULL
and	NULL
third	NULL
screenings	NULL
using	NULL
the	NULL
antibody	NULL
solution	NULL
left	NULL
from	NULL
the	NULL
first	NULL
screening	NULL
step	NULL
.	NULL

The	NULL
clones	NULL
were	NULL
checked	NULL
in	NULL
parallel	NULL
with	NULL
a	NULL
cell	NULL
culture	NULL
supernatant	NULL
of	NULL
a	NULL
hybridoma	NULL
line	NULL
producing	NULL
a	NULL
monoclonal	NULL
anti-La	NULL
antibody	NULL
(	NULL
termed	NULL
La4B6	NULL
,	NULL
obtained	NULL
by	NULL
immunization	NULL
of	NULL
BAL	NULL
B/c	NULL
mice	NULL
with	NULL
a	NULL
recombinant	NULL
human	NULL
La	NULL
protein	NULL
;	NULL
Troster	NULL
,	NULL
H.	NULL
,	NULL
T.	NULL
Metzger	NULL
,	NULL
R.	NULL
Klein	NULL
,	NULL
G.	NULL
Pollak	NULL
,	NULL
I.	NULL
Semsei	NULL
,	NULL
M.	NULL
Schwemmle	NULL
,	NULL
G.	NULL
Pruijn	NULL
,	NULL
W.	NULL
van	NULL
Venrooij	NULL
,	NULL
and	NULL
M.	NULL
Bachmann	NULL
,	NULL
unpublished	NULL
results	NULL
)	NULL
.	NULL

The	NULL
immunoscreening	NULL
was	NULL
performed	NULL
following	NULL
the	NULL
protocol	NULL
of	NULL
Mierendorf	NULL
et	NULL
al	NULL
.	NULL

(	NULL
22	NULL
)	NULL
.	NULL

A	NULL
total	NULL
amount	NULL
of	NULL
4	NULL
x	NULL
10°	NULL
recombinant	NULL
phages	NULL
were	NULL
screened	NULL
and	NULL
five	NULL
positive	NULL
La	NULL
cDNAs	NULL
were	NULL
isolated	NULL
with	NULL
the	NULL
patient	NULL
's	NULL
antiserum	NULL
.	NULL

In	NULL
addition	NULL
12	NULL
cDNAs	NULL
encoding	NULL
for	NULL
IgG	NULL
heavy	NULL
chains	NULL
were	NULL
coisolated	NULL
,	NULL
which	NULL
was	NULL
not	NULL
surprising	NULL
as	NULL
the	NULL
cDNA	NULL
library	NULL
was	NULL
constructed	NULL
from	NULL
PBL	NULL
and	NULL
screened	NULL
with	NULL
anti-human	NULL
IgG	NULL
antibodies	NULL
.	NULL

The	NULL
coisolated	NULL
IgG	NULL
heavy	NULL
chain	NULL
cDNAs	NULL
were	NULL
differentiated	NULL
from	NULL
the	NULL
La	NULL
cDNAs	NULL
by	NULL
(	NULL
a	NULL
)	NULL
their	NULL
different	NULL
restriction	NULL
enzyme	NULL
analysis	NULL
pattern	NULL
and	NULL
(	NULL
b	NULL
)	NULL
sequencing	NULL
.	NULL

Isolation	NULL
and	NULL
storage	NULL
of	NULL
the	NULL
clones	NULL
was	NULL
done	NULL
according	NULL
to	NULL
Sambrook	NULL
et	NULL
al	NULL
.	NULL

(	NULL
23	NULL
)	NULL
.	NULL

Phagemids	NULL
(	NULL
pBluescript	NULL
SK	NULL
(	NULL
-	NULL
)	NULL
)	NULL
were	NULL
excised	NULL
from	NULL
A	NULL
phages	NULL
during	NULL
an	NULL
in	NULL
vivo	NULL
excision	NULL
procedure	NULL
described	NULL
by	NULL
Stratagene	NULL
using	NULL
the	NULL
filamentous	NULL
helper	NULL
phage	NULL
strain	NULL
R408	NULL
and	NULL
the	NULL
bacterial	NULL
strain	NULL
XL1-Blue	NULL
as	NULL
a	NULL
host	NULL
(	NULL
23	NULL
)	NULL
.	NULL

Construction	NULL
of	NULL
Deletion	NULL
Clones	NULL
.	NULL

-	NULL
The	NULL
two	NULL
clones	NULL
termed	NULL
La19	NULL
and	NULL
La23	NULL
,	NULL
which	NULL
contained	NULL
the	NULL
largest	NULL
inserts	NULL
,	NULL
were	NULL
selected	NULL
for	NULL
sequencing	NULL
.	NULL

The	NULL
other	NULL
cDNAs	NULL
were	NULL
only	NULL
sequenced	NULL
from	NULL
the	NULL
3'-and	NULL
the	NULL
5'-end	NULL
to	NULL
characterize	NULL
them	NULL
as	NULL
La	NULL
cDNAs	NULL
.	NULL

DNA	NULL
was	NULL
prepared	NULL
from	NULL
small	NULL
scale	NULL
cultures	NULL
(	NULL
up	NULL
to	NULL
12	NULL
ml	NULL
)	NULL
using	NULL
the	NULL
protocol	NULL
of	NULL
Holmes	NULL
and	NULL
Quigley	NULL
(	NULL
24	NULL
)	NULL
modified	NULL
according	NULL
to	NULL
Sambrook	NULL
et	NULL
al	NULL
.	NULL

(	NULL
23	NULL
)	NULL
.	NULL

To	NULL
create	NULL
deletion	NULL
clones	NULL
the	NULL
method	NULL
originally	NULL
described	NULL
by	NULL
Henikoff	NULL
(	NULL
25	NULL
)	NULL
was	NULL
used	NULL
.	NULL

The	NULL
DNA	NULL
to	NULL
be	NULL
deleted	NULL
was	NULL
cut	NULL
with	NULL
BstXI	NULL
and	NULL
EcoRI	NULL
from	NULL
which	NULL
site	NULL
deletions	NULL
started	NULL
.	NULL

Construction	NULL
of	NULL
a	NULL
Genomic	NULL
Subclone	NULL
For	NULL
subcloning	NULL
of	NULL
the	NULL
genomic	NULL
fragment	NULL
derived	NULL
from	NULL
the	NULL
charon	NULL
phage	NULL
ALaZ-1	NULL
(	NULL
17	NULL
)	NULL
,	NULL
which	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
Dr.	NULL
Keene	NULL
(	NULL
Duke	NULL
University	NULL
,	NULL
Durham	NULL
,	NULL
NC	NULL
)	NULL
,	NULL
the	NULL
``	NULL
shot	NULL
gun	NULL
``	NULL
cloning	NULL
technique	NULL
was	NULL
used	NULL
.	NULL

13	NULL
ng	NULL
of	NULL
ALa2-1	NULL
DNA	NULL
was	NULL
digested	NULL
with	NULL
EcoRI	NULL
(	NULL
5	NULL
U/pg	NULL
DNA	NULL
in	NULL
2x	NULL
One-Phor-All-Buffer	NULL
PLUS	NULL
[	NULL
Pharmacia	NULL
LKB	NULL
,	NULL
Freiburg	NULL
,	NULL
Germany	NULL
]	NULL
)	NULL
.	NULL

In	NULL
earlier	NULL
studies	NULL
Chambers	NULL
et	NULL
al	NULL
.	NULL

(	NULL
17	NULL
)	NULL
had	NULL
shown	NULL
that	NULL
a	NULL
digestion	NULL
of	NULL
genomic	NULL
DNA	NULL
with	NULL
EcoRI	NULL
resulted	NULL
among	NULL
other	NULL
fragments	NULL
2060	NULL
in	NULL
a	NULL
4.6-kb	NULL
fragment	NULL
of	NULL
the	NULL
La	NULL
gene	NULL
.	NULL

According	NULL
to	NULL
our	NULL
calculations	NULL
the	NULL
molecular	NULL
mass	NULL
of	NULL
this	NULL
fragment	NULL
might	NULL
be	NULL
about	NULL
4.8	NULL
kb	NULL
.	NULL

The	NULL
reaction	NULL
was	NULL
stopped	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
EDTA	NULL
to	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
17	NULL
mM	NULL
followed	NULL
by	NULL
a	NULL
heat	NULL
treatment	NULL
for	NULL
20	NULL
min	NULL
at	NULL
68°C	NULL
.	NULL

The	NULL
pBluescript	NULL
SK	NULL
(	NULL
-	NULL
)	NULL
vector	NULL
DNA	NULL
(	NULL
Stratagene	NULL
)	NULL
was	NULL
digested	NULL
with	NULL
EcoRI	NULL
(	NULL
2.5	NULL
U/	NULL
ug	NULL
of	NULL
DNA	NULL
)	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
0.88	NULL
ug	NULL
DNA/	NULL
ul	NULL
in	NULL
2x	NULL
One-Phor-All-Buffer	NULL
PLUS	NULL
.	NULL

After	NULL
dilution	NULL
(	NULL
1:4	NULL
)	NULL
and	NULL
an	NULL
in-activation	NULL
step	NULL
by	NULL
heating	NULL
to	NULL
68°C	NULL
for	NULL
20	NULL
min	NULL
,	NULL
calf	NULL
intestine	NULL
phosphatase	NULL
(	NULL
CIP	NULL
;	NULL
Boehringer	NULL
Mannheim	NULL
,	NULL
Mannheim	NULL
,	NULL
Germany	NULL
)	NULL
was	NULL
added	NULL
(	NULL
0.3	NULL
U	NULL
CIP/ug	NULL
DNA	NULL
)	NULL
and	NULL
incubated	NULL
for	NULL
30	NULL
min	NULL
at	NULL
37°C	NULL
in	NULL
the	NULL
recommended	NULL
buffer	NULL
(	NULL
10x	NULL
:	NULL
0.5	NULL
M	NULL
Tris/HCI	NULL
,	NULL
pH	NULL
8.5	NULL
;	NULL
1	NULL
mM	NULL
EDTA	NULL
)	NULL
.	NULL

The	NULL
enzyme	NULL
was	NULL
inactivated	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
EDTA	NULL
(	NULL
16	NULL
mM	NULL
final	NULL
concentration	NULL
)	NULL
in	NULL
combination	NULL
with	NULL
heating	NULL
for	NULL
30	NULL
min	NULL
to	NULL
75°C	NULL
.	NULL

The	NULL
ligation	NULL
of	NULL
the	NULL
EcoRI-fragments	NULL
with	NULL
the	NULL
phosphatase-treated	NULL
EcoRI-digested	NULL
vector	NULL
DNA	NULL
took	NULL
place	NULL
in	NULL
a	NULL
10	NULL
pl	NULL
volume	NULL
at	NULL
16°C	NULL
overnight	NULL
.	NULL

The	NULL
reaction	NULL
mixture	NULL
consisted	NULL
of	NULL
200	NULL
ng	NULL
vector	NULL
DNA	NULL
,	NULL
30	NULL
ng	NULL
of	NULL
EcoRI-fragments	NULL
in	NULL
Tris/HCl	NULL
,	NULL
pH	NULL
7.5	NULL
containing	NULL
1	NULL
mM	NULL
ATP	NULL
,	NULL
1	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
and	NULL
5	NULL
mM	NULL
MgCl	NULL
;	NULL
.	NULL

Then	NULL
the	NULL
ligation	NULL
reaction	NULL
was	NULL
adjusted	NULL
to	NULL
a	NULL
volume	NULL
of	NULL
100	NULL
pul	NULL
with	NULL
H	NULL
;	NULL
0	NULL
and	NULL
added	NULL
to	NULL
200	NULL
pl	NULL
of	NULL
competent	NULL
E.	NULL
coli	NULL
XL1-Blue	NULL
cells	NULL
for	NULL
transformation	NULL
according	NULL
to	NULL
Sambrook	NULL
et	NULL
al	NULL
.	NULL

(	NULL
23	NULL
)	NULL
.	NULL

The	NULL
bacteria	NULL
were	NULL
plated	NULL
on	NULL
ampicillin	NULL
(	NULL
150	NULL
ug/ml	NULL
)	NULL
agar	NULL
containing	NULL
2.5	NULL
mM	NULL
isopropyl	NULL
B-o-thiogalactoside	NULL
(	NULL
IPTG	NULL
)	NULL
and	NULL
0.4	NULL
%	NULL
(	NULL
wt/vol	NULL
)	NULL
X-Gal	NULL
in	NULL
order	NULL
to	NULL
discriminate	NULL
religated	NULL
vector	NULL
DNA	NULL
(	NULL
blue	NULL
colonies	NULL
)	NULL
from	NULL
colonies	NULL
containing	NULL
vectors	NULL
with	NULL
inserts	NULL
(	NULL
white	NULL
colonies	NULL
)	NULL
.	NULL

Plasmid	NULL
DNAs	NULL
derived	NULL
from	NULL
white	NULL
colonies	NULL
were	NULL
found	NULL
to	NULL
contain	NULL
the	NULL
desired	NULL
4.8-kb	NULL
fragment	NULL
of	NULL
the	NULL
La	NULL
gene	NULL
.	NULL

Southern	NULL
Blotting	NULL
.	NULL

DNA	NULL
was	NULL
isolated	NULL
as	NULL
basically	NULL
described	NULL
by	NULL
Chirgwin	NULL
et	NULL
al	NULL
.	NULL

(	NULL
19	NULL
)	NULL
using	NULL
minor	NULL
modifications	NULL
according	NULL
to	NULL
Semsei	NULL
and	NULL
Cutler	NULL
(	NULL
20	NULL
)	NULL
.	NULL

The	NULL
DNA	NULL
was	NULL
digested	NULL
with	NULL
EcoRI	NULL
and	NULL
13	NULL
ug	NULL
of	NULL
DNA	NULL
per	NULL
lane	NULL
were	NULL
loaded	NULL
on	NULL
an	NULL
0.7	NULL
%	NULL
agarose	NULL
gel	NULL
.	NULL

The	NULL
gel	NULL
was	NULL
run	NULL
for	NULL
16	NULL
h	NULL
with	NULL
1.8	NULL
V/cm	NULL
.	NULL

Southern	NULL
blotting	NULL
was	NULL
performed	NULL
according	NULL
to	NULL
Sambrook	NULL
et	NULL
al	NULL
.	NULL

(	NULL
23	NULL
)	NULL
.	NULL

After	NULL
transfer	NULL
onto	NULL
a	NULL
positively	NULL
charged	NULL
Nylon	NULL
membrane	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
)	NULL
the	NULL
DNA	NULL
was	NULL
cross-linked	NULL
by	NULL
UV	NULL
irradiation	NULL
with	NULL
120	NULL
mJ	NULL
using	NULL
a	NULL
Stratalinker	NULL
1800	NULL
(	NULL
Stratagene	NULL
)	NULL
followed	NULL
by	NULL
a	NULL
heat	NULL
treatment	NULL
for	NULL
60	NULL
min	NULL
at	NULL
80°C	NULL
.	NULL

Hybridizations	NULL
and	NULL
labelings	NULL
of	NULL
the	NULL
DNA	NULL
were	NULL
performed	NULL
according	NULL
to	NULL
the	NULL
nonradioactive	NULL
detection	NULL
system	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
}	NULL
.	NULL

The	NULL
signals	NULL
were	NULL
developed	NULL
using	NULL
anti-DIG	NULL
antibodies	NULL
covalently	NULL
linked	NULL
to	NULL
either	NULL
alkaline	NULL
phosphatase	NULL
and	NULL
CSPD	NULL
(	NULL
TRopix	NULL
,	NULL
Serva	NULL
Heidelberg	NULL
,	NULL
Germany	NULL
)	NULL
as	NULL
substrate	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

2	NULL
A	NULL
)	NULL
or	NULL
peroxidase	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
)	NULL
and	NULL
the	NULL
enhanced	NULL
chemiluminescence	NULL
(	NULL
ECL	NULL
)	NULL
detection	NULL
system	NULL
(	NULL
Amersham-Buchler	NULL
,	NULL
Braunschweig	NULL
,	NULL
Germany	NULL
)	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
B	NULL
and	NULL
C	NULL
)	NULL
.	NULL

Between	NULL
the	NULL
three	NULL
hybridizations	NULL
,	NULL
membrane	NULL
stripping	NULL
was	NULL
performed	NULL
as	NULL
follows	NULL
.	NULL

The	NULL
filter	NULL
was	NULL
washed	NULL
twice	NULL
in	NULL
0.1	NULL
%	NULL
SDS	NULL
at	NULL
room	NULL
temperature	NULL
followed	NULL
by	NULL
a	NULL
proteinase	NULL
K	NULL
treatment	NULL
(	NULL
1	NULL
mg/ml	NULL
)	NULL
in	NULL
0.1	NULL
%	NULL
SDS	NULL
for	NULL
35	NULL
min	NULL
at	NULL
55°C	NULL
and	NULL
10	NULL
min	NULL
at	NULL
65°C	NULL
.	NULL

Afterward	NULL
the	NULL
membrane	NULL
was	NULL
further	NULL
stripped	NULL
as	NULL
described	NULL
by	NULL
Sambrook	NULL
et	NULL
al	NULL
.	NULL

(	NULL
23	NULL
)	NULL
.	NULL

For	NULL
this	NULL
purpose	NULL
the	NULL
blot	NULL
was	NULL
washed	NULL
with	NULL
50	NULL
%	NULL
formamide	NULL
,	NULL
2x	NULL
SSPE	NULL
at	NULL
room	NULL
temperature	NULL
and	NULL
in	NULL
the	NULL
same	NULL
buffer	NULL
at	NULL
65°C	NULL
for	NULL
45	NULL
min	NULL
.	NULL

The	NULL
membrane	NULL
was	NULL
rinsed	NULL
in	NULL
0.1	NULL
%	NULL
SDS	NULL
,	NULL
0.1x	NULL
SSC	NULL
at	NULL
room	NULL
temperature	NULL
,	NULL
dried	NULL
on	NULL
3MM-paper	NULL
(	NULL
Whatman	NULL
International	NULL
Ltd.	NULL
,	NULL
Maidstone	NULL
,	NULL
UK	NULL
)	NULL
and	NULL
stored	NULL
at	NULL
room	NULL
temperature	NULL
in	NULL
the	NULL
dark	NULL
and	NULL
dry	NULL
.	NULL

PCR	NULL
.	NULL

PCR	NULL
was	NULL
performed	NULL
using	NULL
a	NULL
TC9600	NULL
Cycler	NULL
(	NULL
Perkin-Elmer	NULL
,	NULL
Uberlingen	NULL
,	NULL
Germany	NULL
)	NULL
.	NULL

The	NULL
50-ul	NULL
assay	NULL
in	NULL
1x	NULL
Taq	NULL
buffer	NULL
contained	NULL
2	NULL
U	NULL
Taq	NULL
polymerase	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
)	NULL
,	NULL
1.5	NULL
mM	NULL
MgC	NULL
]	NULL
,	NULL
5	NULL
%	NULL
(	NULL
vol/vol	NULL
)	NULL
DMSO	NULL
,	NULL
200	NULL
mM	NULL
of	NULL
each	NULL
dNTP	NULL
,	NULL
20	NULL
pmol	NULL
of	NULL
each	NULL
primer	NULL
,	NULL
and	NULL
100	NULL
ng	NULL
of	NULL
genomic	NULL
DNA	NULL
or	NULL
1	NULL
ng	NULL
of	NULL
plasmid	NULL
DNA	NULL
.	NULL

Cycling	NULL
was	NULL
started	NULL
by	NULL
heating	NULL
for	NULL
2	NULL
min	NULL
to	NULL
94°C	NULL
.	NULL

40	NULL
cycles	NULL
followed	NULL
,	NULL
each	NULL
consisting	NULL
of	NULL
15	NULL
s	NULL
at	NULL
94°C	NULL
,	NULL
15	NULL
s	NULL
at	NULL
55-60°C	NULL
depending	NULL
on	NULL
the	NULL
primer	NULL
pairs	NULL
used	NULL
,	NULL
and	NULL
15-60	NULL
s	NULL
at	NULL
72°C	NULL
depending	NULL
on	NULL
the	NULL
length	NULL
of	NULL
the	NULL
resulting	NULL
fragments	NULL
.	NULL

Then	NULL
the	NULL
temperature	NULL
Alternative	NULL
Transcript	NULL
Encoding	NULL
for	NULL
the	NULL
Autoantigen	NULL
La/SS-B	NULL
was	NULL
held	NULL
for	NULL
10	NULL
min	NULL
at	NULL
72°C	NULL
and	NULL
cooled	NULL
down	NULL
to	NULL
4°C	NULL
.	NULL

6	NULL
ul	NULL
of	NULL
the	NULL
respective	NULL
assay	NULL
were	NULL
taken	NULL
,	NULL
and	NULL
1.5	NULL
pl	NULL
of	NULL
sample	NULL
buffer	NULL
(	NULL
40	NULL
%	NULL
sucrose	NULL
,	NULL
0.25	NULL
%	NULL
bromophenol	NULL
blue	NULL
in	NULL
H	NULL
;	NULL
0	NULL
)	NULL
was	NULL
added	NULL
and	NULL
applied	NULL
to	NULL
a	NULL
1.5-1.8	NULL
%	NULL
agarose	NULL
(	NULL
Biozym	NULL
,	NULL
Hameln	NULL
,	NULL
Germany	NULL
)	NULL
gel	NULL
in	NULL
TAE	NULL
buffer	NULL
(	NULL
40	NULL
mM	NULL
Tris-acetate	NULL
,	NULL
pH	NULL
8.0	NULL
;	NULL
1	NULL
mM	NULL
EDTA	NULL
)	NULL
.	NULL

For	NULL
determination	NULL
of	NULL
the	NULL
molecular	NULL
weights	NULL
of	NULL
the	NULL
PCR	NULL
products	NULL
250	NULL
ng	NULL
of	NULL
the	NULL
DNA	NULL
molecular	NULL
weight	NULL
marker	NULL
VI	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
)	NULL
was	NULL
run	NULL
in	NULL
parallel	NULL
.	NULL

The	NULL
gels	NULL
were	NULL
run	NULL
for	NULL
10	NULL
min	NULL
at	NULL
5	NULL
V/cm	NULL
and	NULL
120	NULL
min	NULL
at	NULL
3	NULL
V/cm	NULL
and	NULL
stained	NULL
with	NULL
ethidium	NULL
bromide	NULL
.	NULL

Photographs	NULL
were	NULL
taken	NULL
with	NULL
polaroid	NULL
film	NULL
667	NULL
.	NULL

DNA	NULL
Sequence	NULL
Analysis	NULL
The	NULL
DNA	NULL
for	NULL
sequencing	NULL
of	NULL
the	NULL
cDNAs	NULL
was	NULL
prepared	NULL
by	NULL
alkaline	NULL
lysis	NULL
miniprep	NULL
method	NULL
according	NULL
to	NULL
Sambrook	NULL
et	NULL
al	NULL
.	NULL

(	NULL
23	NULL
)	NULL
.	NULL

The	NULL
DNA	NULL
samples	NULL
were	NULL
sequenced	NULL
using	NULL
the	NULL
automatic	NULL
fluorescent	NULL
DNA	NULL
sequencing	NULL
system	NULL
of	NULL
the	NULL
EMBL	NULL
.	NULL

The	NULL
sequences	NULL
were	NULL
evaluated	NULL
running	NULL
the	NULL
evaluation	NULL
program	NULL
COMGRA	NULL
on	NULL
a	NULL
486	NULL
PC	NULL
system	NULL
.	NULL

DNA	NULL
comparison	NULL
and	NULL
alignments	NULL
were	NULL
performed	NULL
using	NULL
the	NULL
program	NULL
package	NULL
HUSAR	NULL
of	NULL
the	NULL
DKFZ	NULL
(	NULL
Heidelberg	NULL
,	NULL
Germany	NULL
)	NULL
.	NULL

The	NULL
genomic	NULL
sequences	NULL
were	NULL
prepared	NULL
from	NULL
genomic	NULL
DNA	NULL
isolated	NULL
from	NULL
different	NULL
tissues	NULL
including	NULL
PBL	NULL
of	NULL
the	NULL
patient	NULL
(	NULL
Ma	NULL
;	NULL
[	NULL
8	NULL
]	NULL
)	NULL
with	NULL
pSS	NULL
,	NULL
an	NULL
SLE	NULL
patient	NULL
(	NULL
p62	NULL
)	NULL
,	NULL
and	NULL
her	NULL
baby	NULL
born	NULL
with	NULL
AV	NULL
block	NULL
(	NULL
p61	NULL
)	NULL
,	NULL
as	NULL
well	NULL
as	NULL
several	NULL
healthy	NULL
donors	NULL
,	NULL
and	NULL
the	NULL
subclone	NULL
derived	NULL
from	NULL
the	NULL
genomic	NULL
clone	NULL
ALaZ-1	NULL
(	NULL
see	NULL
above	NULL
)	NULL
,	NULL
the	NULL
liver	NULL
of	NULL
a	NULL
tumor	NULL
patient	NULL
(	NULL
We	NULL
)	NULL
,	NULL
and	NULL
the	NULL
embryonic	NULL
spleen	NULL
.	NULL

The	NULL
genomic	NULL
sequence	NULL
between	NULL
the	NULL
promotor	NULL
upstream	NULL
of	NULL
the	NULL
exon	NULL
1	NULL
and	NULL
the	NULL
end	NULL
of	NULL
the	NULL
exon	NULL
2	NULL
was	NULL
determined	NULL
for	NULL
the	NULL
subclone	NULL
prepared	NULL
from	NULL
the	NULL
genomic	NULL
clone	NULL
ALa2Z-1	NULL
(	NULL
see	NULL
above	NULL
)	NULL
as	NULL
well	NULL
as	NULL
for	NULL
the	NULL
genomic	NULL
DNA	NULL
of	NULL
the	NULL
patient	NULL
(	NULL
Ma	NULL
)	NULL
.	NULL

For	NULL
that	NULL
purpose	NULL
overlapping	NULL
PCR	NULL
fragments	NULL
were	NULL
prepared	NULL
and	NULL
sequenced	NULL
using	NULL
the	NULL
Cycle	NULL
Sequencing	NULL
Kit	NULL
from	NULL
Pharmacia	NULL
LKB	NULL
and/or	NULL
the	NULL
PCR	NULL
fragments	NULL
were	NULL
directly	NULL
sequenced	NULL
{	NULL
see	NULL
below	NULL
)	NULL
.	NULL

In	NULL
the	NULL
case	NULL
of	NULL
the	NULL
GC-rich	NULL
region	NULL
between	NULL
the	NULL
exon	NULL
1	NULL
and	NULL
the	NULL
oligo	NULL
(	NULL
dT	NULL
)	NULL
-tail	NULL
the	NULL
PCR	NULL
fragments	NULL
prepared	NULL
were	NULL
not	NULL
only	NULL
directly	NULL
sequenced	NULL
but	NULL
subcloned	NULL
into	NULL
pBluescript	NULL
and	NULL
at	NULL
least	NULL
three	NULL
subclones	NULL
were	NULL
sequenced	NULL
.	NULL

The	NULL
following	NULL
primers	NULL
were	NULL
used	NULL
for	NULL
sequencing	NULL
of	NULL
the	NULL
genomic	NULL
region	NULL
between	NULL
promoter	NULL
1	NULL
and	NULL
the	NULL
exon	NULL
2	NULL
:	NULL
P1	NULL
(	NULL
GCACTTCACAT-GAATGGAGG	NULL
)	NULL
;	NULL
P2	NULL
(	NULL
GAGTCGTTGCTGTTGCTGTTTG	NULL
)	NULL
;	NULL
P3	NULL
(	NULL
GCACAGGCTCACAAACAGCAAC	NULL
)	NULL
;	NULL
P4	NULL
(	NULL
GCTGTTTGTGAG-CCTGTGCGGCGGC	NULL
)	NULL
;	NULL
P5	NULL
(	NULL
GT	NULL
TCCT	NULL
TAGATACTCTATGC	NULL
)	NULL
;	NULL
P6	NULL
(	NULL
CGCTTTACTAGTGCGCGACTGCGCGTTTCC	NULL
)	NULL
;	NULL
P7	NULL
(	NULL
AAG-ACGCAATGGGGATGAGG	NULL
)	NULL
;	NULL
P8	NULL
(	NULL
ACCGCCTTCTAGTCTCAC-CGAA	NULL
)	NULL
;	NULL
P9	NULL
(	NULL
ACAAGCCTTCGGTGAGACTAGA	NULL
)	NULL
;	NULL
P10	NULL
(	NULL
CCC-ACCTCCCCAGAAACTTTACAG	NULL
)	NULL
;	NULL
PM	NULL
(	NULL
GCACGGGGTAAA-CGCCGGAGGGTTC	NULL
)	NULL
;	NULL
P12	NULL
(	NULL
CTGAAACCTGATGTGAGCGAT-G	NULL
)	NULL
;	NULL
P13	NULL
(	NULL
GCCAAATAGGTTTTGCAGGGTG	NULL
)	NULL
;	NULL
P14	NULL
(	NULL
ATGCTTC-CAGGAAGTGTACC	NULL
)	NULL
;	NULL
P15	NULL
(	NULL
GT	NULL
TAGTATGACCACATTCTCCC	NULL
)	NULL
;	NULL
P16	NULL
(	NULL
GGACCCTTTTGTAGCTTCTC	NULL
)	NULL
;	NULL
P17	NULL
(	NULL
AGTTCAAGACCA-GCCTGACC	NULL
)	NULL
;	NULL
P18	NULL
(	NULL
CT	NULL
TCACTTAGCTGGTCAAGC	NULL
)	NULL
;	NULL
P19	NULL
(	NULL
CTC-AACAAAGCAACACTTTGG	NULL
)	NULL
;	NULL
P20	NULL
(	NULL
TCACCATTTTCAGCC-ATTGCGG	NULL
)	NULL
;	NULL
P21	NULL
(	NULL
GATGACAGATTTTGGCCTCCAG	NULL
)	NULL
.	NULL

Cycle	NULL
sequencing	NULL
was	NULL
performed	NULL
using	NULL
the	NULL
Cycle	NULL
Sequencing	NULL
Kit	NULL
from	NULL
Pharmacia	NULL
LKB	NULL
and	NULL
the	NULL
Cycler	NULL
TC9600	NULL
(	NULL
Perkin-Elmer	NULL
)	NULL
.	NULL

Four	NULL
caps	NULL
were	NULL
prepared	NULL
by	NULL
adding	NULL
to	NULL
each	NULL
2	NULL
ul	NULL
of	NULL
one	NULL
of	NULL
the	NULL
four	NULL
termination	NULL
mixtures	NULL
(	NULL
A	NULL
,	NULL
C	NULL
,	NULL
G	NULL
,	NULL
T	NULL
)	NULL
and	NULL
stored	NULL
at	NULL
4°C	NULL
until	NULL
use	NULL
.	NULL

Then	NULL
master	NULL
mixes	NULL
were	NULL
prepared	NULL
consisting	NULL
of	NULL
2	NULL
ul	NULL
primer	NULL
solutions	NULL
containing	NULL
up	NULL
to	NULL
10	NULL
pmol	NULL
primer	NULL
,	NULL
5	NULL
pul	NULL
of	NULL
5x	NULL
sequencing	NULL
buffer	NULL
,	NULL
1	NULL
ul	NULL
dNTP	NULL
mix	NULL
,	NULL
1	NULL
ul	NULL
Tth	NULL
(	NULL
Thermus	NULL
thermophilus	NULL
)	NULL
DNA	NULL
polymerase	NULL
(	NULL
1	NULL
U/ul	NULL
)	NULL
,	NULL
1	NULL
ul	NULL
«	NULL
-	NULL
[	NULL
P	NULL
]	NULL
dATP	NULL
(	NULL
3,000	NULL
Ci/mmol	NULL
;	NULL
NEN	NULL
,	NULL
Dreieich	NULL
,	NULL
Germany	NULL
)	NULL
,	NULL
and	NULL
2	NULL
ug	NULL
of	NULL
template	NULL
DNA	NULL
.	NULL

5	NULL
pul	NULL
of	NULL
the	NULL
respective	NULL
master	NULL
mix	NULL
were	NULL
added	NULL
to	NULL
each	NULL
of	NULL
the	NULL
four	NULL
termination	NULL
mixtures	NULL
(	NULL
A	NULL
,	NULL
C	NULL
,	NULL
G	NULL
,	NULL
T	NULL
)	NULL
.	NULL

Cycling	NULL
was	NULL
started	NULL
by	NULL
heating	NULL
for	NULL
2	NULL
min	NULL
to	NULL
95°C	NULL
.	NULL

Then	NULL
25	NULL
(	NULL
to	NULL
50	NULL
)	NULL
cycles	NULL
followed	NULL
,	NULL
each	NULL
consisting	NULL
of	NULL
30	NULL
s	NULL
at	NULL
95°C	NULL
,	NULL
36	NULL
s	NULL
at	NULL
55°C	NULL
,	NULL
and	NULL
84	NULL
s	NULL
at	NULL
72°C	NULL
.	NULL

Finally	NULL
the	NULL
reaction	NULL
mix	NULL
2061	NULL
Troster	NULL
et	NULL
al	NULL
.	NULL

tures	NULL
were	NULL
held	NULL
for	NULL
5	NULL
min	NULL
at	NULL
72°C	NULL
and	NULL
cooled	NULL
to	NULL
4°C	NULL
until	NULL
the	NULL
addition	NULL
of	NULL
3	NULL
pl	NULL
of	NULL
the	NULL
stop	NULL
solution	NULL
.	NULL

The	NULL
radioactivity	NULL
labeled	NULL
samples	NULL
were	NULL
separated	NULL
on	NULL
a	NULL
sequencing	NULL
gel	NULL
using	NULL
the	NULL
sequencing	NULL
system	NULL
LKB	NULL
2010	NULL
Macrophor	NULL
(	NULL
Pharmacia	NULL
LKB	NULL
)	NULL
.	NULL

Fo	NULL
)	NULL
r	NULL
directly	NULL
sequencing	NULL
of	NULL
the	NULL
PCR	NULL
fragments	NULL
the	NULL
T7-Sequenase-Kit	NULL
from	NULL
Pharmacia	NULL
LKB	NULL
was	NULL
used	NULL
according	NULL
to	NULL
the	NULL
following	NULL
procedure	NULL
.	NULL

The	NULL
PCR	NULL
products	NULL
were	NULL
first	NULL
separated	NULL
on	NULL
3	NULL
to	NULL
4	NULL
%	NULL
NuSieve	NULL
(	NULL
Biozym	NULL
)	NULL
agarose	NULL
gels	NULL
and	NULL
eluted	NULL
using	NULL
GENECLEAN	NULL
II	NULL
(	NULL
Dianova	NULL
,	NULL
Hamburg	NULL
,	NULL
Germany	NULL
)	NULL
.	NULL

4	NULL
ul	NULL
of	NULL
isolated	NULL
DNA	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
10-20	NULL
ug/ml	NULL
were	NULL
added	NULL
to	NULL
2	NULL
pul	NULL
annealing	NULL
buffer	NULL
.	NULL

Then	NULL
2	NULL
ul	NULL
primer	NULL
solutions	NULL
containing	NULL
300	NULL
ng	NULL
of	NULL
primer	NULL
were	NULL
added	NULL
,	NULL
followed	NULL
by	NULL
1.2	NULL
ul	NULL
of	NULL
NP-40	NULL
(	NULL
5	NULL
%	NULL
)	NULL
and	NULL
2.8	NULL
ul	NULL
H	NULL
,	NULL
O	NULL
.	NULL

The	NULL
complete	NULL
annealing	NULL
mixture	NULL
(	NULL
12	NULL
ul	NULL
)	NULL
was	NULL
briefly	NULL
centrifuged	NULL
using	NULL
an	NULL
Eppendorf	NULL
centrifuge	NULL
(	NULL
Eppendorf	NULL
,	NULL
Hamburg	NULL
,	NULL
Germany	NULL
)	NULL
and	NULL
rapidly	NULL
heated	NULL
to	NULL
95°C	NULL
for	NULL
3	NULL
min	NULL
.	NULL

Then	NULL
the	NULL
annealing	NULL
mixture	NULL
was	NULL
immediately	NULL
transferred	NULL
to	NULL
liquid	NULL
nitrogen	NULL
.	NULL

For	NULL
labeling	NULL
6	NULL
pl	NULL
of	NULL
the	NULL
labeling	NULL
mixture	NULL
(	NULL
T7-Sequenase-Kit	NULL
;	NULL
Pharmacia	NULL
,	NULL
LKB	NULL
)	NULL
,	NULL
which	NULL
consisted	NULL
of	NULL
3	NULL
ul	NULL
Labeling-Mix	NULL
,	NULL
0.5	NULL
ul	NULL
e	NULL
«	NULL
-	NULL
[	NULL
*S	NULL
}	NULL
-dATP	NULL
(	NULL
1,000	NULL
Ci/mmol	NULL
)	NULL
,	NULL
2	NULL
ul	NULL
T7-polymerase	NULL
(	NULL
2	NULL
U/	NULL
ul	NULL
)	NULL
,	NULL
and	NULL
0.5	NULL
ul	NULL
NP-40	NULL
(	NULL
5	NULL
%	NULL
)	NULL
,	NULL
was	NULL
added	NULL
.	NULL

4	NULL
pl	NULL
aliquots	NULL
were	NULL
used	NULL
for	NULL
each	NULL
dNTP	NULL
.	NULL

The	NULL
labeling	NULL
reaction	NULL
was	NULL
started	NULL
by	NULL
adding	NULL
and	NULL
briefly	NULL
centrifuging	NULL
of	NULL
the	NULL
4	NULL
ul	NULL
labeling	NULL
mixtures	NULL
to	NULL
the	NULL
respective	NULL
mixture	NULL
consisting	NULL
of	NULL
2	NULL
ul	NULL
of	NULL
one	NULL
of	NULL
the	NULL
four	NULL
short	NULL
mixes	NULL
(	NULL
A	NULL
,	NULL
C	NULL
,	NULL
G	NULL
,	NULL
T	NULL
)	NULL
and	NULL
0.5	NULL
ul	NULL
NP-40	NULL
(	NULL
5	NULL
%	NULL
)	NULL
.	NULL

Labeling	NULL
was	NULL
performed	NULL
for	NULL
5	NULL
min	NULL
at	NULL
37°C	NULL
.	NULL

Then	NULL
2	NULL
pul	NULL
of	NULL
a	NULL
chase	NULL
mixture	NULL
consisting	NULL
of	NULL
2	NULL
ul	NULL
dNTPs	NULL
(	NULL
2.5	NULL
mM	NULL
)	NULL
,	NULL
2	NULL
al	NULL
NP-40	NULL
(	NULL
5	NULL
%	NULL
)	NULL
,	NULL
2	NULL
ul	NULL
NaCl	NULL
(	NULL
500	NULL
mM	NULL
)	NULL
,	NULL
and	NULL
14	NULL
ul	NULL
H	NULL
;	NULL
O0	NULL
was	NULL
added	NULL
,	NULL
briefly	NULL
centrifuged	NULL
and	NULL
incubated	NULL
for	NULL
5	NULL
min	NULL
at	NULL
37°C	NULL
.	NULL

Finally	NULL
,	NULL
the	NULL
reaction	NULL
was	NULL
stopped	NULL
by	NULL
adding	NULL
5	NULL
pl	NULL
stop	NULL
solution	NULL
and	NULL
briefly	NULL
centrifuging	NULL
.	NULL

5-RACE	NULL
.	NULL

For	NULL
an	NULL
analysis	NULL
of	NULL
the	NULL
5'-ends	NULL
of	NULL
the	NULL
La	NULL
RNAs	NULL
we	NULL
chose	NULL
the	NULL
5-RACE	NULL
system	NULL
supplied	NULL
by	NULL
GIBCO	NULL
BRL	NULL
(	NULL
Eggenstein	NULL
,	NULL
Germany	NULL
)	NULL
.	NULL

It	NULL
includes	NULL
a	NULL
first	NULL
strand	NULL
cDNA	NULL
synthesis	NULL
and	NULL
an	NULL
PCR	NULL
amplification	NULL
step	NULL
.	NULL

During	NULL
reverse	NULL
transcription	NULL
,	NULL
40	NULL
U	NULL
of	NULL
RNase	NULL
inhibitor	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
)	NULL
was	NULL
added	NULL
to	NULL
each	NULL
sample	NULL
.	NULL

The	NULL
total	NULL
RNA	NULL
samples	NULL
used	NULL
were	NULL
isolated	NULL
from	NULL
either	NULL
(	NULL
adult	NULL
)	NULL
liver	NULL
of	NULL
the	NULL
tumor	NULL
patient	NULL
(	NULL
We	NULL
)	NULL
with	NULL
liver	NULL
metastasis	NULL
(	NULL
1.4	NULL
ug	NULL
)	NULL
,	NULL
human	NULL
embryonic	NULL
(	NULL
20	NULL
week	NULL
)	NULL
spleen	NULL
(	NULL
5	NULL
ug	NULL
)	NULL
,	NULL
PBL	NULL
of	NULL
the	NULL
patient	NULL
(	NULL
Ma	NULL
)	NULL
with	NULL
pSS	NULL
(	NULL
0.3	NULL
ug	NULL
)	NULL
,	NULL
PBL	NULL
of	NULL
a	NULL
(	NULL
adult	NULL
)	NULL
control	NULL
person	NULL
(	NULL
0.6	NULL
ug	NULL
)	NULL
.	NULL

The	NULL
reactions	NULL
and	NULL
the	NULL
following	NULL
5'-RACE	NULL
steps	NULL
were	NULL
performed	NULL
according	NULL
to	NULL
the	NULL
instructions	NULL
of	NULL
the	NULL
supplier	NULL
.	NULL

For	NULL
the	NULL
first	NULL
strand	NULL
synthesis	NULL
a	NULL
primer	NULL
locating	NULL
within	NULL
the	NULL
exon	NULL
3	NULL
was	NULL
used	NULL
(	NULL
TGTCCCGTG-GCAAATTGAAGTCGCC	NULL
)	NULL
.	NULL

Amplification	NULL
was	NULL
performed	NULL
using	NULL
the	NULL
primers	NULL
P20	NULL
and	NULL
P12	NULL
in	NULL
combination	NULL
with	NULL
the	NULL
Anchor	NULL
Primer	NULL
of	NULL
the	NULL
5'-RACE	NULL
kit	NULL
(	NULL
GIBCO	NULL
BRL	NULL
,	NULL
Eggenstein	NULL
,	NULL
Germany	NULL
)	NULL
.	NULL

Results	NULL
Based	NULL
on	NULL
the	NULL
suggestion	NULL
that	NULL
the	NULL
development	NULL
of	NULL
autoantibodies	NULL
to	NULL
La	NULL
protein	NULL
in	NULL
patients	NULL
with	NULL
SLE	NULL
and	NULL
pSS	NULL
is	NULL
at	NULL
least	NULL
partially	NULL
driven	NULL
by	NULL
the	NULL
autoantigen	NULL
itself	NULL
,	NULL
one	NULL
might	NULL
expect	NULL
an	NULL
altered	NULL
expression	NULL
of	NULL
the	NULL
La	NULL
gene	NULL
in	NULL
patients	NULL
in	NULL
dependence	NULL
on	NULL
disease	NULL
conditions	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
looked	NULL
for	NULL
alternative	NULL
forms	NULL
of	NULL
La	NULL
mRNAs	NULL
in	NULL
tissue	NULL
obtained	NULL
from	NULL
a	NULL
La	NULL
positive	NULL
pSS	NULL
patient	NULL
(	NULL
Ma	NULL
)	NULL
(	NULL
8	NULL
)	NULL
.	NULL

Isolation	NULL
of	NULL
Alternative	NULL
La	NULL
cDNAs	NULL
.	NULL

For	NULL
that	NULL
purpose	NULL
a	NULL
cDNA	NULL
library	NULL
was	NULL
prepared	NULL
from	NULL
the	NULL
patient	NULL
's	NULL
PBLs	NULL
.	NULL

This	NULL
cDNA	NULL
library	NULL
was	NULL
screened	NULL
with	NULL
the	NULL
patient	NULL
's	NULL
own	NULL
autoimmune	NULL
serum	NULL
.	NULL

Thereby	NULL
five	NULL
La	NULL
cDNAs	NULL
were	NULL
isolated	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

Three	NULL
of	NULL
them	NULL
had	NULL
derived	NULL
from	NULL
shortened	NULL
La	NULL
mRNAs	NULL
starting	NULL
within	NULL
or	NULL
downstream	NULL
of	NULL
the	NULL
exon	NULL
2	NULL
,	NULL
as	NULL
became	NULL
already	NULL
evidence	NULL
from	NULL
restriction	NULL
enzyme	NULL
fragment	NULL
analysis	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
and	NULL
sequencing	NULL
from	NULL
the	NULL
5'-	NULL
and	NULL
3'-end	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
em	NULL
hiad	NULL
w	NULL
«	NULL
ew	NULL
3	NULL
e	NULL
x	NULL
ew	NULL
w	NULL
leo	NULL
3	NULL
em	NULL
E	NULL
K	NULL
Bg	NULL
Bm	NULL
X	NULL
Bs	NULL
Bm	NULL
Xh	NULL
0	NULL
;	NULL
+	NULL
+	NULL
i_	NULL
%	NULL
+	NULL
+	NULL
+	NULL
--	NULL
+	NULL
X	NULL
K	NULL
E	NULL
Bm	NULL
Bs	NULL
X	NULL
Bm	NULL
Bg	NULL
K	NULL
Xh	NULL
+	NULL
+	NULL
*	NULL
+	NULL
*	NULL
+	NULL
¥	NULL
+	NULL
--	NULL
i	NULL
X	NULL
K	NULL
Bg	NULL
Bm	NULL
X	NULL
Bs	NULL
Bm	NULL
Xh	NULL
©	NULL
.	NULL

+	NULL
+	NULL
%	NULL
+	NULL
+	NULL
x	NULL
R	NULL
E	NULL
Bg	NULL
Bm	NULL
X	NULL
Bs	NULL
Bm	NULL
Xh	NULL
®	NULL
{	NULL
_	NULL
+	NULL
*	NULL
+	NULL
+	NULL
4	NULL
P	NULL
--	NULL
+	NULL
X	NULL
K	NULL
®	NULL
E	NULL
Bm	NULL
X	NULL
Bs	NULL
Bm	NULL
Xh	NULL
X	NULL
K	NULL
Figure	NULL
1	NULL
.	NULL

Characterization	NULL
of	NULL
the	NULL
La	NULL
cDNAs	NULL
isolated	NULL
from	NULL
the	NULL
cDNA	NULL
library	NULL
of	NULL
the	NULL
patient	NULL
with	NULL
pSS	NULL
by	NULL
immunoscreening	NULL
using	NULL
restriction	NULL
enzyme	NULL
fragment	NULL
analysis	NULL
.	NULL

The	NULL
screening	NULL
of	NULL
the	NULL
patient	NULL
's	NULL
cDNA	NULL
library	NULL
with	NULL
her	NULL
own	NULL
autoimmune	NULL
serum	NULL
resulted	NULL
in	NULL
the	NULL
isolation	NULL
of	NULL
five	NULL
cDNAs	NULL
(	NULL
B	NULL
;	NULL
1-5	NULL
)	NULL
that	NULL
had	NULL
been	NULL
derived	NULL
from	NULL
La	NULL
mRNAs	NULL
.	NULL

These	NULL
La	NULL
cDNAs	NULL
showed	NULL
a	NULL
restriction	NULL
enzyme	NULL
fragment	NULL
pattern	NULL
similar	NULL
to	NULL
the	NULL
pattern	NULL
of	NULL
a	NULL
La	NULL
cDNA	NULL
(	NULL
A	NULL
)	NULL
described	NULL
by	NULL
Chan	NULL
et	NULL
al	NULL
.	NULL

(	NULL
13	NULL
)	NULL
.	NULL

The	NULL
clones	NULL
with	NULL
the	NULL
two	NULL
longest	NULL
La	NULL
inserts	NULL
were	NULL
termed	NULL
as	NULL
La23	NULL
(	NULL
1	NULL
)	NULL
and	NULL
La19	NULL
(	NULL
2	NULL
)	NULL
.	NULL

The	NULL
insert	NULL
in	NULL
the	NULL
clone	NULL
La19	NULL
has	NULL
the	NULL
opposite	NULL
orientation	NULL
as	NULL
in	NULL
the	NULL
other	NULL
La	NULL
clones	NULL
.	NULL

residual	NULL
two	NULL
La	NULL
cDNAs	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
clones	NULL
1	NULL
and	NULL
2	NULL
,	NULL
which	NULL
were	NULL
termed	NULL
as	NULL
La23	NULL
and	NULL
La19	NULL
)	NULL
were	NULL
sequenced	NULL
and	NULL
their	NULL
sequence	NULL
was	NULL
given	NULL
to	NULL
the	NULL
EMBL	NULL
Data	NULL
Library	NULL
(	NULL
EMBL	NULL
accession	NULL
number	NULL
X69804	NULL
)	NULL
.	NULL

Both	NULL
La	NULL
cDNAs	NULL
were	NULL
found	NULL
to	NULL
start	NULL
upstream	NULL
of	NULL
the	NULL
exon	NULL
2	NULL
,	NULL
but	NULL
displayed	NULL
the	NULL
following	NULL
three	NULL
unusual	NULL
properties	NULL
:	NULL
(	NULL
a	NULL
)	NULL
they	NULL
started	NULL
at	NULL
their	NULL
5°	NULL
terminus	NULL
with	NULL
an	NULL
oligo	NULL
(	NULL
dT	NULL
)	NULL
-stretch	NULL
;	NULL
(	NULL
b	NULL
)	NULL
as	NULL
already	NULL
evident	NULL
from	NULL
the	NULL
restriction	NULL
enzyme	NULL
fragment	NULL
analysis	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
,	NULL
the	NULL
La	NULL
cDNA	NULL
insert	NULL
was	NULL
inverted	NULL
in	NULL
the	NULL
clone	NULL
La19	NULL
,	NULL
probably	NULL
due	NULL
to	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
oligo	NULL
(	NULL
dT	NULL
)	NULL
-stretch	NULL
,	NULL
and	NULL
;	NULL
(	NULL
c	NULL
)	NULL
upstream	NULL
of	NULL
exon	NULL
2	NULL
,	NULL
exactly	NULL
at	NULL
the	NULL
splice	NULL
site	NULL
,	NULL
the	NULL
complete	NULL
exon	NULL
1	NULL
was	NULL
replaced	NULL
by	NULL
an	NULL
unknown	NULL
5'-terminal	NULL
sequence	NULL
,	NULL
termed	NULL
exon	NULL
1	NULL
'	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Downstream	NULL
of	NULL
the	NULL
exon	NULL
2	NULL
,	NULL
the	NULL
sequence	NULL
was	NULL
identical	NULL
to	NULL
the	NULL
described	NULL
La	NULL
sequences	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Southern	NULL
Blot	NULL
Analysis	NULL
.	NULL

To	NULL
rule	NULL
out	NULL
a	NULL
cloning	NULL
artifact	NULL
or	NULL
the	NULL
isolation	NULL
of	NULL
a	NULL
splicing	NULL
intermediate	NULL
the	NULL
genomic	NULL
origin	NULL
of	NULL
the	NULL
exon	NULL
1	NULL
'	NULL
sequence	NULL
was	NULL
determined	NULL
.	NULL

By	NULL
performing	NULL
Southern	NULL
blot	NULL
experiments	NULL
with	NULL
genomic	NULL
DNA	NULL
of	NULL
healthy	NULL
individuals	NULL
and	NULL
the	NULL
patient	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
the	NULL
exon	NULL
1	NULL
'	NULL
was	NULL
located	NULL
on	NULL
a	NULL
4.8-kb	NULL
EcoRI	NULL
fragment	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
A	NULL
)	NULL
,	NULL
which	NULL
was	NULL
described	NULL
as	NULL
containing	NULL
the	NULL
exons	NULL
1	NULL
and	NULL
2	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
intron	NULL
between	NULL
them	NULL
(	NULL
17	NULL
)	NULL
.	NULL

In	NULL
agreement	NULL
,	NULL
the	NULL
same	NULL
fragment	NULL
also	NULL
hybridized	NULL
to	NULL
a	NULL
probe	NULL
being	NULL
specific	NULL
for	NULL
the	NULL
exon	NULL
1	NULL
sequence	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
B	NULL
)	NULL
and	NULL
was	NULL
confirmed	NULL
to	NULL
be	NULL
a	NULL
part	NULL
of	NULL
the	NULL
La	NULL
gene	NULL
,	NULL
as	NULL
it	NULL
also	NULL
hybridized	NULL
to	NULL
a	NULL
probe	NULL
containing	NULL
the	NULL
complete	NULL
La	NULL
cDNA	NULL
sequence	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
C	NULL
)	NULL
.	NULL

From	NULL
this	NULL
experiment	NULL
it	NULL
became	NULL
also	NULL
evident	NULL
that	NULL
the	NULL
exon	NULL
1	NULL
'	NULL
sequence	NULL
is	NULL
not	NULL
a	NULL
patient	NULL
specific	NULL
sequence	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
A-C	NULL
,	NULL
lane	NULL
c	NULL
)	NULL
but	NULL
exists	NULL
in	NULL
healthy	NULL
donors	NULL
as	NULL
well	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
A-C	NULL
,	NULL
lanes	NULL
a	NULL
and	NULL
b	NULL
)	NULL
.	NULL

The	NULL
Genomic	NULL
Origin	NULL
of	NULL
the	NULL
Alternative	NULL
La	NULL
cDNAs	NULL
.	NULL

-	NULL
'The	NULL
next	NULL
steps	NULL
were	NULL
to	NULL
isolate	NULL
the	NULL
4.8-kb	NULL
fragment	NULL
containing	NULL
the	NULL
exon	NULL
1	NULL
'	NULL
sequence	NULL
and	NULL
to	NULL
develop	NULL
a	NULL
sequencing	NULL
scheme	NULL
that	NULL
allowed	NULL
us	NULL
to	NULL
compare	NULL
the	NULL
sequences	NULL
from	NULL
healthy	NULL
donors	NULL
and	NULL
patients	NULL
.	NULL

For	NULL
that	NULL
purpose	NULL
the	NULL
4.8-kb	NULL
fragment	NULL
was	NULL
subcloned	NULL
from	NULL
the	NULL
genomic	NULL
clone	NULL
ALa2-1	NULL
(	NULL
17	NULL
)	NULL
into	NULL
pBluescript	NULL
SK	NULL
(	NULL
-	NULL
)	NULL
and	NULL
sequenced	NULL
starting	NULL
upstream	NULL
of	NULL
the	NULL
proposed	NULL
promoter	NULL
of	NULL
exon	NULL
1	NULL
going	NULL
downstream	NULL
through	NULL
the	NULL
intron	NULL
into	NULL
the	NULL
2062	NULL
(	NULL
I	NULL
)	NULL
[	NULL
La19/23	NULL
]	NULL
TPTTT	NULL
...	NULL
...	NULL
.	NULL

1	NULL
ACCTCCACCGCCTTCTAGTCTCACCGAAGGCTTGTGGCCATCTCTGTAAA	NULL
50	NULL
51	NULL
GTTTCTGGGGAGGTGGGCACGGGGTAAACGCCGGAGGGTTCTGTGGAGCC	NULL
100	NULL
101	NULL
TATGGGACTGACTGGAGGCCAAAGAACTTTGGGCCGCAGATGTACACCAG	NULL
150	NULL
Gd	NULL
10d	NULL
(	NULL
II	NULL
)	NULL
Lo..	NULL
clk	NULL
k	NULL
eee	NULL
v	NULL
ed	NULL
dea	NULL
ek	NULL
re	NULL
rr	NULL
enn	NULL
seee	NULL
21	NULL
151	NULL
CGTCACTCTTTTGGTCTGTTAGGGCCTTCATCGCTCACATCAGGTTTCAG	NULL
200	NULL
PL	NULL
arb	NULL
O	NULL
ELH	NULL
LH	NULL
Ib	NULL
d	NULL
22	NULL
GTCGTTGCTGTTGCTGTTTGTGAGCCTGTGGCGC	NULL
...	NULL
...	NULL
GectTcTtere	NULL
65	NULL
-	NULL
400.	NULL
.	NULL

-	NULL
.	NULL

201	NULL
TGTGAAACGGGAAAACATAGCCGTAATGGCTGAAAATGGTGATAATGAAA	NULL
250	NULL
1	NULL
J	NULL
Hr	NULL
don	NULL
ened	NULL
AAO	NULL
EEE	NULL
EH	NULL
66	NULL
GGCCGGAACCTTAAAGATAGCCGTAATGGCTGAAAATGGTGATAATGAAA	NULL
115	NULL
251	NULL
AGATGGCTGC	NULL
...	NULL
...	NULL
[	NULL
Lik	NULL
.	NULL

ks	NULL
.	NULL

AACTAATAAAATATATACTATATGAAA	NULL
1750	NULL
aceon	NULL
don	NULL
aoa	NULL
oct	NULL
AAG	NULL
UA	NULL
116	NULL
e	NULL
AACTAATAAAATATATACTATATGAAA	NULL
1615	NULL
Figure	NULL
2	NULL
.	NULL

Characterization	NULL
of	NULL
the	NULL
alternative	NULL
form	NULL
of	NULL
La	NULL
mRNA	NULL
.	NULL

A	NULL
comparison	NULL
of	NULL
the	NULL
sequence	NULL
derived	NULL
from	NULL
the	NULL
La	NULL
cDNAs	NULL
La19	NULL
and	NULL
La23	NULL
(	NULL
I	NULL
;	NULL
EMBL	NULL
accession	NULL
number	NULL
X69804	NULL
)	NULL
with	NULL
the	NULL
human	NULL
La	NULL
cDNA	NULL
described	NULL
by	NULL
Chan	NULL
et	NULL
al	NULL
.	NULL

(	NULL
13	NULL
)	NULL
(	NULL
IF	NULL
;	NULL
EMBL	NULL
accession	NULL
number	NULL
X13697	NULL
)	NULL
was	NULL
performed	NULL
.	NULL

Upstream	NULL
of	NULL
the	NULL
acceptor	NULL
splice	NULL
site	NULL
at	NULL
exon	NULL
2	NULL
(	NULL
nt	NULL
216	NULL
;	NULL
[	NULL
J	NULL
]	NULL
)	NULL
the	NULL
sequences	NULL
differed	NULL
,	NULL
whereas	NULL
the	NULL
sequence	NULL
downstream	NULL
of	NULL
the	NULL
exon	NULL
1	NULL
'	NULL
is	NULL
identical	NULL
to	NULL
the	NULL
sequence	NULL
described	NULL
by	NULL
Chan	NULL
et	NULL
al	NULL
.	NULL

(	NULL
13	NULL
)	NULL
.	NULL

The	NULL
La	NULL
cDNAs	NULL
La19	NULL
and	NULL
La23	NULL
started	NULL
with	NULL
an	NULL
oligo	NULL
(	NULL
dT	NULL
)	NULL
-tail	NULL
of	NULL
different	NULL
length	NULL
(	NULL
La19	NULL
,	NULL
31	NULL
(	NULL
dT	NULL
)	NULL
-residues	NULL
;	NULL
La23	NULL
,	NULL
52	NULL
(	NULL
dT	NULL
)	NULL
-residues	NULL
)	NULL
.	NULL

At	NULL
the	NULL
genomic	NULL
level	NULL
the	NULL
length	NULL
of	NULL
the	NULL
(	NULL
dT	NULL
)	NULL
-tail	NULL
was	NULL
determined	NULL
with	NULL
23	NULL
(	NULL
dT	NULL
)	NULL
-residues	NULL
(	NULL
see	NULL
also	NULL
Fig	NULL
.	NULL

4	NULL
B	NULL
)	NULL
.	NULL

exon	NULL
2	NULL
using	NULL
a	NULL
series	NULL
of	NULL
primers	NULL
as	NULL
schematically	NULL
summarized	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
A	NULL
.	NULL

The	NULL
resulting	NULL
complete	NULL
genomic	NULL
sequence	NULL
was	NULL
given	NULL
to	NULL
the	NULL
EMBL	NULL
Data	NULL
Library	NULL
(	NULL
EMBL	NULL
accession	NULL
number	NULL
235127	NULL
)	NULL
and	NULL
is	NULL
partially	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
B	NULL
.	NULL

We	NULL
identified	NULL
the	NULL
exon	NULL
1	NULL
'	NULL
sequence	NULL
,	NULL
including	NULL
its	NULL
oligo	NULL
(	NULL
dT	NULL
)	NULL
-tail	NULL
,	NULL
325	NULL
nt	NULL
downstream	NULL
of	NULL
the	NULL
exon	NULL
1	NULL
donor	NULL
splice	NULL
site	NULL
.	NULL

From	NULL
this	NULL
result	NULL
we	NULL
concluded	NULL
that	NULL
(	NULL
a	NULL
)	NULL
the	NULL
exon	NULL
1	NULL
'	NULL
sequence	NULL
is	NULL
a	NULL
part	NULL
of	NULL
the	NULL
intron	NULL
between	NULL
exon	NULL
1	NULL
and	NULL
2	NULL
;	NULL
(	NULL
b	NULL
)	NULL
the	NULL
alternative	NULL
La	NULL
cDNAs	NULL
La19	NULL
and	NULL
La23	NULL
must	NULL
have	NULL
been	NULL
derived	NULL
from	NULL
processed	NULL
hnRNAs	NULL
;	NULL
and	NULL
(	NULL
c	NULL
)	NULL
the	NULL
5-terminal	NULL
oligo	NULL
(	NULL
dT	NULL
)	NULL
-tail	NULL
of	NULL
La19	NULL
and	NULL
La23	NULL
was	NULL
not	NULL
the	NULL
result	NULL
of	NULL
a	NULL
cloning	NULL
artifact	NULL
.	NULL

A	NULL
B	NULL
C	NULL
a	NULL
b	NULL
c	NULL
a	NULL
b	NULL
c	NULL
a	NULL
b	NULL
c	NULL
-	NULL
6.56	NULL
-	NULL
4.36	NULL
Figure	NULL
3	NULL
.	NULL

Southern	NULL
blot	NULL
experiment	NULL
of	NULL
the	NULL
La	NULL
gene	NULL
.	NULL

Genomic	NULL
DNAs	NULL
obtained	NULL
from	NULL
liver	NULL
of	NULL
a	NULL
tumor	NULL
patient	NULL
(	NULL
We	NULL
,	NULL
lane	NULL
a	NULL
)	NULL
,	NULL
from	NULL
PBL	NULL
of	NULL
either	NULL
a	NULL
healthy	NULL
donor	NULL
(	NULL
lane	NULL
b	NULL
)	NULL
,	NULL
or	NULL
from	NULL
the	NULL
patient	NULL
(	NULL
Ma	NULL
)	NULL
with	NULL
pSS	NULL
(	NULL
lane	NULL
c	NULL
)	NULL
were	NULL
analyzed	NULL
.	NULL

The	NULL
same	NULL
blot	NULL
was	NULL
hybridized	NULL
three	NULL
times	NULL
with	NULL
probes	NULL
specific	NULL
for	NULL
either	NULL
exon	NULL
1	NULL
'	NULL
(	NULL
4	NULL
)	NULL
or	NULL
exon	NULL
1	NULL
(	NULL
B	NULL
)	NULL
or	NULL
the	NULL
complete	NULL
La	NULL
gene	NULL
(	NULL
C	NULL
)	NULL
.	NULL

Alternative	NULL
Transcript	NULL
Encoding	NULL
for	NULL
the	NULL
Autoantigen	NULL
La/SS-B	NULL
EXON	NULL
1	NULL
C	NULL
P1+	NULL
5	NULL
'	NULL
10	NULL
GGGCTGGGGT	NULL
60	NULL
CTAACACAAA	NULL
110	NULL
CAATCTGTTT	NULL
160	NULL
GCAGCCGCGC	NULL
210	NULL
CTGCCCACCC	NULL
260	NULL
GCGCTTTAGG	NULL
310	NULL
GTTTGTGAGC	NULL
360	NULL
TAACTCTCGG	NULL
410	NULL
CGCGACTGCG	NULL
460	NULL
CCTCGCCTTC	NULL
510	NULL
GCGGCGGAGC	NULL
560	NULL
ATGCGGGATC	NULL
610	NULL
CGGTTGCTTA	NULL
660	NULL
TITTITITTTT	NULL
710	NULL
CTTGTGGCCA	NULL
760	NULL
CCGGAGGGTT	NULL
810	NULL
GGGCCGCAGA	NULL
860	NULL
TCGCTCACAT	NULL
910	NULL
ATTTACAGTC	NULL
2270	NULL
AACATTATCT	NULL
2320	NULL
ATTTGGGAAA	NULL
2370	NULL
AAAGATGGCT	NULL
EXON	NULL
1	NULL
``	NULL
P+	NULL
+P12	NULL
P13+	NULL
20	NULL
ACAGACGCCG	NULL
70	NULL
CTAGCAGCCA	NULL
120	NULL
Pil	NULL
»	NULL
P15+	NULL
30	NULL
TCCAGAAATA	NULL
80	NULL
TTCCCCTACA	NULL
130	NULL
GGGATTGAGG	NULL
GCocaactcc	NULL
(	NULL
i	NULL
)	NULL
3333	NULL
»	NULL
170	NULL
ATGCTCAGAG	NULL
220	NULL
AGGCCGCAAG	NULL
270	NULL
lew	NULL
ucie/elelclclelc	NULL
}	NULL
320	NULL
CTGTGGCece	NULL
370	NULL
TGGCTAATGA	NULL
420	NULL
CGTTTCCGTT	NULL
erd	NULL
470	NULL
CTCACGTTCA	NULL
520	NULL
CGAGGGGGCG	NULL
570	NULL
CTGSGGTTCC	NULL
620	NULL
GAGACGGGAC	NULL
670	NULL
TTTTTITTTTT	NULL
720	NULL
TCTCTGTAAA	NULL
770	NULL
CTGTGGAGCC	NULL
820	NULL
TGTACACCAG	NULL
870	NULL
CAGGTTTCAG	NULL
920	NULL
GTACATTCTG	NULL
2280	NULL
TTCTATTCTT	NULL
U	NULL
TTTTACAGAT	NULL
2380	NULL
GCCCTGGAGG	NULL
2063	NULL
180	NULL
CACAGGGACC	NULL
230	NULL
AGCTGCCGGG	NULL
280	NULL
GCGCTGGGaAG	NULL
330	NULL
GCTTCTGTGG	NULL
380	NULL
GAAGCTACAA	NULL
+P16	NULL
PiT+	NULL
40	NULL
CTTAAAAATA	NULL
90	NULL
ACCTGGAGTA	NULL
140	NULL
AGGGTCCCTG	NULL
190	NULL
GCTCCACCTC	NULL
240	NULL
ACGGTCCCCA	NULL
EXON	NULL
2	NULL
50	NULL
AATGTTTATA	NULL
100	NULL
CTTTTTAACC	NULL
150	NULL
GGAGGCCCCG	NULL
200	NULL
GTCCGTGGCC	NULL
250	NULL
TCTTCTTGGA	NULL
ead	NULL
290	NULL
GTGGAGTCGT	NULL
340	NULL
GCCGGAACCT	NULL
390	NULL
AAGGGTCCGC	NULL
(	NULL
ii	NULL
)	NULL
333+	NULL
430	NULL
CTTTACTGCT	NULL
480	NULL
GGCCGAGCGC	NULL
530	NULL
CGGGCGG6Ccee	NULL
580	NULL
CCGCACGTGG	NULL
630	NULL
TGTGGCTGCC	NULL
680	NULL
ACCTCCACCG	NULL
730	NULL
GTTTCTGGGG	NULL
780	NULL
TATGGGACTG	NULL
830	NULL
CGTCACTCTT	NULL
880	NULL
TGTGAAACGG	NULL
«	NULL
//	NULL
...	NULL
2290	NULL
GAGTTTTATA	NULL
2340	NULL
AGCCGCAATG	NULL
2390	NULL
CCAAAATCTG	NULL
Troster	NULL
et	NULL
440	NULL
TCTCGCGGCG	NULL
490	NULL
CGCGTececCc	NULL
540	NULL
CGAGGCTGCC	NULL
590	NULL
CTGGTGCCCA	NULL
640	NULL
CTCATCCCCA	NULL
690	NULL
CCTTCTAGTC	NULL
740	NULL
AGGTGGGCAC	NULL
790	NULL
ACTGGAGGCC	NULL
s40	NULL
TTGGTCTGTT	NULL
U4	NULL
s90	NULL
GAAAACGTGG	NULL
2250	NULL
CGGGATATTA	NULL
2300	NULL
TAAAAAATAA	NULL
2350	NULL
GCTGAAAATG	NULL
2400	NULL
TCATCAAATT	NULL
300	NULL
TGCTGTTGCT	NULL
U	NULL
-	NULL
350	NULL
TAAAGGTGAG	NULL
400	NULL
TTTGCTGGTG	NULL
450	NULL
TCCGTCCGCC	NULL
500	NULL
GCAGCCGGAG	NULL
550	NULL
CCCGCGAGGA	NULL
600	NULL
GGCAGTTCCG	NULL
650	NULL
TTGCGTCTTT	NULL
700	NULL
TCACCGAAGG	NULL
750	NULL
GGGGTAAACG	NULL
800	NULL
AAAGAACTTT	NULL
850	NULL
900	NULL
GTAATATTTC	NULL
2260	NULL
ATACTTTGTA	NULL
2310	NULL
CTTTATGCTA	NULL
2360	NULL
GTGATAATGA	NULL
I	NULL
GAG	NULL
3	NULL
'	NULL
Figure	NULL
4	NULL
.	NULL

The	NULL
promoter	NULL
regions	NULL
,	NULL
the	NULL
exon	NULL
1	NULL
,	NULL
the	NULL
intron	NULL
containing	NULL
the	NULL
exon	NULL
1	NULL
%	NULL
,	NULL
and	NULL
exon	NULL
2	NULL
of	NULL
the	NULL
La/SS-B	NULL
gene	NULL
of	NULL
DNA	NULL
of	NULL
the	NULL
patient	NULL
(	NULL
Ma	NULL
)	NULL
and	NULL
the	NULL
genomic	NULL
clone	NULL
ALa2-1	NULL
.	NULL

(	NULL
4	NULL
)	NULL
The	NULL
genomic	NULL
region	NULL
starting	NULL
upstream	NULL
of	NULL
the	NULL
promoter	NULL
of	NULL
exon	NULL
1	NULL
and	NULL
ending	NULL
downstream	NULL
of	NULL
the	NULL
exon	NULL
2	NULL
was	NULL
determined	NULL
using	NULL
the	NULL
21	NULL
primers	NULL
(	NULL
P1	NULL
to	NULL
P21	NULL
(	NULL
see	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
as	NULL
schematically	NULL
shown	NULL
.	NULL

The	NULL
complete	NULL
sequence	NULL
is	NULL
available	NULL
from	NULL
the	NULL
EMBL	NULL
Data	NULL
Library	NULL
(	NULL
EMBL	NULL
accession	NULL
number	NULL
235127	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Sequencing	NULL
started	NULL
118	NULL
nt	NULL
upstream	NULL
of	NULL
the	NULL
promoter	NULL
region	NULL
(	NULL
(	NULL
i	NULL
)	NULL
===	NULL
>	NULL
=	NULL
)	NULL
described	NULL
by	NULL
Chambers	NULL
et	NULL
al	NULL
.	NULL

(	NULL
17	NULL
)	NULL
;	NULL
nt	NULL
240	NULL
transcription	NULL
start	NULL
site	NULL
(	NULL
m	NULL
}	NULL
of	NULL
exon	NULL
1	NULL
;	NULL
nt	NULL
240-345	NULL
exon	NULL
1	NULL
;	NULL
nt	NULL
345	NULL
(	NULL
4	NULL
)	NULL
donor	NULL
splice	NULL
site	NULL
of	NULL
exon	NULL
1	NULL
;	NULL
(	NULL
#	NULL
i	NULL
)	NULL
====	NULL
putative	NULL
alternative	NULL
TFIID	NULL
binding	NULL
site	NULL
(	NULL
TACAAA	NULL
;	NULL
see	NULL
also	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
;	NULL
nt	NULL
413	NULL
transcription	NULL
start	NULL
site	NULL
(	NULL
m	NULL
)	NULL
of	NULL
exon	NULL
1	NULL
'	NULL
as	NULL
determined	NULL
with	NULL
5-RACE	NULL
;	NULL
nt	NULL
413-886	NULL
exon	NULL
1	NULL
'	NULL
;	NULL
nt	NULL
648-886	NULL
5	NULL
``	NULL
-end	NULL
of	NULL
the	NULL
La	NULL
cDNAs	NULL
La19	NULL
and	NULL
La23	NULL
;	NULL
nt	NULL
886	NULL
(	NULL
1	NULL
)	NULL
donor	NULL
splice	NULL
site	NULL
of	NULL
exon	NULL
1	NULL
'	NULL
;	NULL
nt	NULL
921-2240	NULL
of	NULL
the	NULL
intron	NULL
containing	NULL
at	NULL
nt	NULL
1604-1904	NULL
an	NULL
Alu	NULL
repeat	NULL
are	NULL
not	NULL
shown	NULL
(	NULL
...	NULL
//	NULL
...	NULL
)	NULL
;	NULL
nt	NULL
2328	NULL
acceptor	NULL
splice	NULL
site	NULL
(	NULL
4	NULL
)	NULL
of	NULL
exon	NULL
2	NULL
;	NULL
nt	NULL
2329-2403	NULL
exon	NULL
2	NULL
;	NULL
nt	NULL
2403	NULL
(	NULL
4	NULL
)	NULL
donor	NULL
splice	NULL
site	NULL
of	NULL
exon	NULL
2	NULL
.	NULL

The	NULL
same	NULL
sequencing	NULL
scheme	NULL
was	NULL
then	NULL
used	NULL
to	NULL
sequence	NULL
the	NULL
genomic	NULL
DNA	NULL
of	NULL
the	NULL
patient	NULL
(	NULL
Ma	NULL
)	NULL
.	NULL

The	NULL
sequence	NULL
of	NULL
the	NULL
genomic	NULL
DNA	NULL
of	NULL
the	NULL
patient	NULL
(	NULL
Ma	NULL
)	NULL
differed	NULL
from	NULL
ALaZ-1	NULL
at	NULL
nt	NULL
2003	NULL
with	NULL
respect	NULL
to	NULL
a	NULL
conversion	NULL
of	NULL
the	NULL
nt	NULL
T	NULL
to	NULL
C.	NULL
Moreover	NULL
,	NULL
in	NULL
one	NULL
allele	NULL
of	NULL
the	NULL
patients	NULL
'	NULL
DNA	NULL
a	NULL
deletion	NULL
of	NULL
the	NULL
two	NULL
nts	NULL
(	NULL
CA	NULL
(	NULL
1266/1267	NULL
)	NULL
was	NULL
found	NULL
.	NULL

However	NULL
this	NULL
deletion	NULL
and	NULL
the	NULL
mutation	NULL
is	NULL
not	NULL
common	NULL
to	NULL
other	NULL
patients	NULL
,	NULL
as	NULL
they	NULL
were	NULL
not	NULL
found	NULL
in	NULL
the	NULL
DNA	NULL
of	NULL
a	NULL
female	NULL
SLE	NULL
patient	NULL
or	NULL
her	NULL
baby	NULL
born	NULL
with	NULL
AV	NULL
block	NULL
.	NULL

A	NULL
further	NULL
point	NULL
mutation	NULL
(	NULL
C	NULL
to	NULL
A	NULL
)	NULL
was	NULL
found	NULL
in	NULL
the	NULL
sequence	NULL
of	NULL
the	NULL
tumor	NULL
patient	NULL
(	NULL
We	NULL
)	NULL
with	NULL
liver	NULL
metastasis	NULL
at	NULL
nt	NULL
495	NULL
.	NULL

GCN4-HIS3	NULL
.	NULL

4	NULL
Ap-1_cs4	NULL
Ap-1_cs3	NULL
GTTTGTGAGCCTGTGECGCGSCTTCTGTGGGCCGGAACCTTAAAGGTGAGTAACTCTCGG	NULL
=113	NULL
=	NULL
--	NULL
--	NULL
--	NULL
--	NULL
¥	NULL
--	NULL
--	NULL
~-~-~	NULL
¥==-=	NULL
--	NULL
-~~	NULL
+	NULL
~54	NULL
CAAACACTCGGACACCGCSCCGAAGACACCCGGCCTTGGAATTTCCACTCATTGAGAGCC	NULL
TFIID-EIIa	NULL
¥	NULL
TGGCTAATGAGAAGCTACAAAAGGGTCCGCTTTGCTGGTGCGCGACTECECGTTICCGTT	NULL
~§3	NULL
~~~	NULL
+	NULL
8	NULL
ACCGATTACTCTTCGATGTTTTCCCAGGCGAAACGACCACGCGCTGACGCGCAAAGGCAA	NULL
spi_cs3	NULL
(	NULL
Spi	NULL
)	NULL
-U2sn8	NULL
.	NULL

spi-sv40.4	NULL
Spl-IB-3.2	NULL
Sp1_cs2	NULL
Bop1_asi	NULL
LSF-SV40	NULL
Spi-IE-4/5.2	NULL
Spl-IE~-3.5	NULL
Spl-IR-3.4	NULL
PEa3_cs	NULL
TTR_inverted	NULL
Pu_box	NULL
TTR_inverted	NULL
UCB.1	NULL
Spl-IE~3.1	NULL
PEA3_RS	NULL
zeste-Ubx	NULL
CTTTACTGCTTCTCGCGGCGTCCGTCCGCCCCTCGCCTTCCTCACGTTCAGECCGAGCGC	NULL
EAintnintalatatatalat	NULL
k====~	NULL
--	NULL
-~	NULL
c	NULL
+	NULL
68	NULL
GAAATGACGAAGAGCGCCGCAGGCAGGT	NULL
A	NULL
TGCAAGTCCGSCTCGCG	NULL
EGR-1_CS	NULL
LSF-SV40	NULL
Spl-IE-4/5.2	NULL
Spl-IB-3.5	NULL
Spl-IE-3.4	NULL
Spl-IE-3.1	NULL
sp1_cs3	NULL
(	NULL
Sp1	NULL
)	NULL
~U2snR	NULL
.	NULL

Sp1-8V40.4	NULL
Spl-IE-3.2	NULL
sp1_cs2	NULL
Bepi_rsi	NULL
AP-2_CS5	NULL
MRE-BP_CS	NULL
KROX24_CS	NULL
AP-2	NULL
CS4	NULL
CGCGTGGGCCGCAGCCGGAGGCGGCGGAGCCGAGGGGECGCGGECGGCGGCGAGGCTGCC	NULL
69	NULL
<	NULL
~===	NULL
--	NULL
--	NULL
Enuintaisttaiatata	NULL
-~	NULL
+	NULL
128	NULL
MyoD-MCK-lef	NULL
NFI	NULL
NFkB_CS4	NULL
_	NULL
agre	NULL
Pu_box	NULL
MCBF_RS	NULL
NFKB	NULL
CS1	NULL
NR	NULL
(	NULL
I	NULL
)	NULL
CS	NULL
uteroglobin_	NULL
coceceaccaaTecoocaTcoressemmecceccacersccrcerecccasecaActIces	NULL
129	NULL
--	NULL
-~	NULL
--	NULL
--	NULL
-	NULL
gece	NULL
+	NULL
188	NULL
GGSCGCTCCTTACGCCCTAGGACCCCAAGGGGCGTGCACCGACCACGGCTCCGTCAAGGC	NULL
Ap-2_cs5	NULL
malr_cs	NULL
HSV	NULL
IE	NULL
repea	NULL
SIF	NULL
core	NULL
RS	NULL
mal'T_CS	NULL
cesT	NULL
189	NULL
--	NULL
--	NULL
--	NULL
--	NULL
~	NULL
gecsccoo	NULL
--	NULL
+	NULL
248	NULL
GCCAACGAATCTCTECCCTGACACCGACGGCAGTAGGGGTAACCCAGARAAAAAAAAAAA	NULL
Figure	NULL
5	NULL
.	NULL

Consensus	NULL
sequences	NULL
for	NULL
transcription	NULL
factors	NULL
.	NULL

The	NULL
genomic	NULL
sequence	NULL
between	NULL
the	NULL
3'-end	NULL
of	NULL
exon	NULL
1	NULL
(	NULL
italics	NULL
)	NULL
and	NULL
the	NULL
oligo	NULL
(	NULL
dT	NULL
)	NULL
-tail	NULL
,	NULL
which	NULL
is	NULL
the	NULL
start	NULL
of	NULL
the	NULL
La	NULL
cDNAs	NULL
La19	NULL
and	NULL
L223	NULL
,	NULL
was	NULL
analyzed	NULL
for	NULL
transcription	NULL
factor	NULL
consensus	NULL
sequences	NULL
using	NULL
the	NULL
program	NULL
Husar	NULL
(	NULL
DKFZ	NULL
)	NULL
.	NULL

In	NULL
agreement	NULL
with	NULL
the	NULL
5-RACE	NULL
result	NULL
,	NULL
a	NULL
TFHD	NULL
binding	NULL
site	NULL
exists	NULL
-37	NULL
nt	NULL
upstream	NULL
of	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
(	NULL
W	NULL
nt	NULL
1	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
sequence	NULL
contains	NULL
a	NULL
series	NULL
of	NULL
further	NULL
putative	NULL
transcription	NULL
factor	NULL
binding	NULL
sites	NULL
,	NULL
including	NULL
a	NULL
NF-KB	NULL
element	NULL
.	NULL

It	NULL
should	NULL
be	NULL
mentioned	NULL
that	NULL
two	NULL
heat	NULL
shock	NULL
protein	NULL
(	NULL
hsp	NULL
)	NULL
70	NULL
transcription	NULL
factor	NULL
consensus	NULL
sequences	NULL
are	NULL
located	NULL
about	NULL
270	NULL
nt	NULL
upstream	NULL
of	NULL
the	NULL
TACAAA	NULL
site	NULL
,	NULL
which	NULL
is	NULL
already	NULL
upstream	NULL
of	NULL
the	NULL
promotor	NULL
for	NULL
the	NULL
exon	NULL
1	NULL
.	NULL

Moreover	NULL
,	NULL
a	NULL
true	NULL
TATA	NULL
box	NULL
locates	NULL
50	NULL
nt	NULL
further	NULL
upstream	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

2064	NULL
Determination	NULL
of	NULL
the	NULL
Alternative	NULL
Transcription	NULL
Initiation	NULL
Site	NULL
-	NULL
As	NULL
the	NULL
oligo	NULL
(	NULL
dT	NULL
)	NULL
-tail	NULL
was	NULL
found	NULL
to	NULL
be	NULL
a	NULL
true	NULL
part	NULL
of	NULL
the	NULL
alternative	NULL
La	NULL
mRNA	NULL
,	NULL
it	NULL
appeared	NULL
rather	NULL
unlikely	NULL
that	NULL
it	NULL
should	NULL
be	NULL
the	NULL
transcription	NULL
initiation	NULL
site	NULL
of	NULL
the	NULL
La	NULL
mRNA	NULL
.	NULL

Therefore	NULL
,	NULL
in	NULL
a	NULL
further	NULL
approach	NULL
we	NULL
looked	NULL
for	NULL
the	NULL
transcription	NULL
initiation	NULL
site	NULL
of	NULL
the	NULL
alternative	NULL
La	NULL
mRNA	NULL
.	NULL

Using	NULL
the	NULL
5'-RACE	NULL
technique	NULL
,	NULL
the	NULL
transcription	NULL
start	NULL
was	NULL
determined	NULL
to	NULL
locate	NULL
235	NULL
nt	NULL
upstream	NULL
of	NULL
the	NULL
oligo	NULL
(	NULL
dT	NULL
)	NULL
-stretch	NULL
,	NULL
which	NULL
is	NULL
68	NULL
nt	NULL
downstream	NULL
of	NULL
the	NULL
exon	NULL
1	NULL
but	NULL
still	NULL
within	NULL
the	NULL
intron	NULL
between	NULL
exon	NULL
1	NULL
and	NULL
exon	NULL
2	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
B	NULL
)	NULL
.	NULL

By	NULL
consequence	NULL
,	NULL
the	NULL
La	NULL
gene	NULL
might	NULL
contain	NULL
two	NULL
promotor	NULL
sites	NULL
.	NULL

One	NULL
upstream	NULL
of	NULL
the	NULL
exon	NULL
1	NULL
and	NULL
an	NULL
alternative	NULL
promotor	NULL
within	NULL
the	NULL
intron	NULL
downstream	NULL
of	NULL
the	NULL
exon	NULL
1	NULL
'	NULL
.	NULL

Indeed	NULL
searching	NULL
for	NULL
hypothetical	NULL
transcription	NULL
factor	NULL
binding	NULL
sites	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
a	NULL
hypothetical	NULL
TFIID	NULL
binding	NULL
site	NULL
was	NULL
identified	NULL
to	NULL
locate	NULL
-37	NULL
nt	NULL
upstream	NULL
of	NULL
the	NULL
determined	NULL
transcriptional	NULL
start	NULL
site	NULL
(	NULL
Figs	NULL
.	NULL

4	NULL
and	NULL
5	NULL
)	NULL
.	NULL

A	NULL
Mechanism	NULL
Leading	NULL
to	NULL
the	NULL
Alternative	NULL
La	NULL
mRNA	NULL
Form	NULL
.	NULL

-	NULL
In	NULL
summary	NULL
,	NULL
we	NULL
conclude	NULL
that	NULL
the	NULL
alternative	NULL
La	NULL
mRNA	NULL
is	NULL
transcribed	NULL
from	NULL
an	NULL
alternative	NULL
promoter	NULL
within	NULL
the	NULL
intron	NULL
and	NULL
represents	NULL
the	NULL
result	NULL
of	NULL
an	NULL
alternative	NULL
splicing	NULL
event	NULL
.	NULL

The	NULL
proposed	NULL
mechanism	NULL
leading	NULL
to	NULL
the	NULL
two	NULL
forms	NULL
of	NULL
La	NULL
mRNAs	NULL
is	NULL
schematically	NULL
summarized	NULL
in	NULL
Fig	NULL
.	NULL

6	NULL
as	NULL
follows	NULL
:	NULL
when	NULL
the	NULL
promotor	NULL
upstream	NULL
of	NULL
exon	NULL
1	NULL
is	NULL
used	NULL
,	NULL
the	NULL
complete	NULL
intron	NULL
between	NULL
exons	NULL
1	NULL
and	NULL
2	NULL
including	NULL
the	NULL
exon	NULL
1	NULL
'	NULL
sequence	NULL
locating	NULL
within	NULL
the	NULL
intron	NULL
is	NULL
removed	NULL
during	NULL
splicing	NULL
.	NULL

If	NULL
the	NULL
promotor	NULL
upstream	NULL
of	NULL
exon	NULL
1	NULL
'	NULL
but	NULL
downstream	NULL
of	NULL
the	NULL
exon	NULL
1	NULL
is	NULL
used	NULL
,	NULL
then	NULL
(	NULL
a	NULL
)	NULL
the	NULL
exon	NULL
1	NULL
is	NULL
not	NULL
transcribed	NULL
and	NULL
(	NULL
b	NULL
)	NULL
an	NULL
alternative	NULL
donor	NULL
splice	NULL
site	NULL
within	NULL
the	NULL
intron	NULL
is	NULL
spliced	NULL
to	NULL
the	NULL
same	NULL
acceptor	NULL
splice	NULL
site	NULL
at	NULL
the	NULL
exon	NULL
2	NULL
.	NULL

At	NULL
the	NULL
mRNA	NULL
level	NULL
this	NULL
results	NULL
in	NULL
a	NULL
complete	NULL
exchange	NULL
of	NULL
the	NULL
exon	NULL
1	NULL
by	NULL
the	NULL
exon	NULL
1	NULL
'	NULL
.	NULL

Properties	NULL
of	NULL
the	NULL
Resulting	NULL
Alternative	NULL
La	NULL
mRNA	NULL
.	NULL

-	NULL
One	NULL
major	NULL
difference	NULL
between	NULL
the	NULL
two	NULL
types	NULL
of	NULL
La	NULL
mRNAs	NULL
is	NULL
based	NULL
on	NULL
the	NULL
existence	NULL
of	NULL
three	NULL
ATGs	NULL
in	NULL
the	NULL
exon	NULL
1	NULL
'	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

7	NULL
,	NULL
there	NULL
are	NULL
two	NULL
stop	NULL
codons	NULL
in	NULL
the	NULL
reading	NULL
frame	NULL
of	NULL
the	NULL
first	NULL
ATG	NULL
.	NULL

The	NULL
second	NULL
ATG	NULL
is	NULL
in	NULL
the	NULL
+1	NULL
and	NULL
the	NULL
third	NULL
ATG	NULL
in	NULL
the	NULL
-1	NULL
frame	NULL
.	NULL

Interestingly	NULL
,	NULL
upstream	NULL
of	NULL
the	NULL
first	NULL
ATG	NULL
there	NULL
are	NULL
two	NULL
GC-rich	NULL
regions	NULL
.	NULL

Further	NULL
Properties	NULL
of	NULL
the	NULL
Analyzed	NULL
Genomic	NULL
Region	NULL
of	NULL
the	NULL
La	NULL
Gene	NULL
.	NULL

Based	NULL
on	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
oligo	NULL
(	NULL
dT	NULL
)	NULL
-tail	NULL
and	NULL
of	NULL
a	NULL
further	NULL
homopolymeric	NULL
sequence	NULL
,	NULL
an	NULL
oligo	NULL
(	NULL
dA	NULL
)	NULL
-tail	NULL
of	NULL
26	NULL
(	NULL
A	NULL
)	NULL
-residues	NULL
(	NULL
nt	NULL
1905-1930	NULL
;	NULL
EMBL	NULL
accession	NULL
number	NULL
235127	NULL
)	NULL
,	NULL
which	NULL
locates	NULL
downstream	NULL
of	NULL
an	NULL
Alu	NULL
repeat	NULL
(	NULL
nt	NULL
1604-1904	NULL
)	NULL
,	NULL
we	NULL
asked	NULL
whether	NULL
the	NULL
alternative	NULL
5	NULL
terminus	NULL
represents	NULL
a	NULL
part	NULL
of	NULL
a	NULL
pseudogene	NULL
.	NULL

Comparison	NULL
with	NULL
the	NULL
EMBL	NULL
Data	NULL
Library	NULL
resulted	NULL
in	NULL
the	NULL
identification	NULL
of	NULL
a	NULL
sequence	NULL
element	NULL
of	NULL
89	NULL
nt	NULL
starting	NULL
153	NULL
nt	NULL
upstream	NULL
of	NULL
the	NULL
oligo	NULL
(	NULL
dT	NULL
)	NULL
-tail	NULL
,	NULL
which	NULL
has	NULL
homologies	NULL
in	NULL
the	NULL
range	NULL
of	NULL
65	NULL
%	NULL
to	NULL
the	NULL
reversed	NULL
sequence	NULL
of	NULL
the	NULL
avian	NULL
myelocytomatosis	NULL
provirus	NULL
and	NULL
pseudorabies	NULL
virus	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
.	NULL

The	NULL
region	NULL
of	NULL
homology	NULL
to	NULL
the	NULL
avian	NULL
myelocytomatosis	NULL
virus	NULL
locates	NULL
within	NULL
the	NULL
v-myc	NULL
region	NULL
of	NULL
the	NULL
gag-myc	NULL
fusion	NULL
protein	NULL
.	NULL

Discussion	NULL
Frequently	NULL
sera	NULL
of	NULL
patients	NULL
with	NULL
pSS	NULL
and	NULL
SLE	NULL
contain	NULL
au-toantibodies	NULL
.	NULL

One	NULL
of	NULL
the	NULL
targets	NULL
of	NULL
the	NULL
ANAs	NULL
is	NULL
the	NULL
nuclear	NULL
autoantigen	NULL
La/SS-B	NULL
(	NULL
7	NULL
)	NULL
.	NULL

Different	NULL
mechanisms	NULL
had	NULL
been	NULL
discussed	NULL
for	NULL
the	NULL
development	NULL
of	NULL
the	NULL
autoantibodies	NULL
directed	NULL
to	NULL
Alternative	NULL
Transcript	NULL
Encoding	NULL
for	NULL
the	NULL
Autoantigen	NULL
La/SS-B	NULL
FA	NULL
_Exo	NULL
``	NULL
~	NULL
+/	NULL
Figure	NULL
6	NULL
.	NULL

Origin	NULL
of	NULL
the	NULL
two	NULL
different	NULL
forms	NULL
of	NULL
La	NULL
mRNAs	NULL
.	NULL

The	NULL
La	NULL
gene	NULL
contains	NULL
two	NULL
alternative	NULL
transcription	NULL
start	NULL
sites	NULL
(	NULL
4	NULL
)	NULL
.	NULL

In	NULL
the	NULL
case	NULL
of	NULL
the	NULL
exon	NULL
1	NULL
containing	NULL
La	NULL
mRNA	NULL
the	NULL
transcription	NULL
start	NULL
was	NULL
originally	NULL
determined	NULL
with	NULL
primer	NULL
extension	NULL
(	NULL
17	NULL
)	NULL
.	NULL

This	NULL
site	NULL
was	NULL
confirmed	NULL
by	NULL
the	NULL
use	NULL
of	NULL
the	NULL
5-RACE	NULL
technique	NULL
.	NULL

The	NULL
same	NULL
technique	NULL
was	NULL
used	NULL
to	NULL
determine	NULL
the	NULL
initiation	NULL
site	NULL
of	NULL
the	NULL
exon	NULL
1	NULL
'	NULL
type	NULL
La	NULL
mRNA	NULL
.	NULL

It	NULL
was	NULL
found	NULL
to	NULL
locate	NULL
in	NULL
the	NULL
intron	NULL
downstream	NULL
of	NULL
the	NULL
exon	NULL
1	NULL
.	NULL

By	NULL
consequence	NULL
,	NULL
the	NULL
two	NULL
forms	NULL
are	NULL
expressed	NULL
as	NULL
follows	NULL
:	NULL
when	NULL
the	NULL
promotor	NULL
upstream	NULL
of	NULL
exon	NULL
Genomic	NULL
level	NULL
10	NULL
20	NULL
30	NULL
40	NULL
50	NULL
5	NULL
'	NULL
TTTCCGTTCT	NULL
TTACTGCTTC	NULL
TCGCéGcGTC	NULL
CeTCceccee	NULL
TCeccTTCcT	NULL
60	NULL
70	NULL
80	NULL
90	NULL
100	NULL
CACGTTCAGG	NULL
CCGAGCGCCG	NULL
CGTGGGCCG	NULL
@	NULL
c	NULL
AGCCGGAGGC	NULL
_	NULL
GGCGGAGCCG	NULL
110	NULL
120	NULL
130	NULL
140	NULL
150	NULL
AGGGGGCGCG	NULL
GGCGGCGece	NULL
AGGCTGCCCC	NULL
CGCGAGGAAT	NULL
GCGGGATCCT	NULL
0	NULL
M	NULL
R	NULL
D__P	NULL
160	NULL
170	NULL
180	NULL
190	NULL
200	NULL
GGGGTTCCCC	NULL
GCACGTGGCT	NULL
GGTGCCCAGG	NULL
CAGTTCCGCG	NULL
GTTGCTTAGA	NULL
0	NULL
G	NULL
V	NULL
P	NULL
R	NULL
T	NULL
W	NULL
L	NULL
V__P_	NULL
R	NULL
g_	NULL
F_R	NULL
G	NULL
A	NULL
L	NULL
E	NULL
210	NULL
220	NULL
230	NULL
240	NULL
250	NULL
GACGGGACTG	NULL
TGGCTGCCCT	NULL
CATCCCCATT	NULL
GCGTCTTTTT	NULL
TTTTTITTTT	NULL
0	NULL
T	NULL
G	NULL
L	NULL
w__L	NULL
_	NULL
_P	NULL
S	NULL
$	NULL
_	NULL
_P_	NULL
L	NULL
R	NULL
L	NULL
F	NULL
FFP	NULL
F	NULL
F	NULL
260	NULL
270	NULL
280	NULL
290	NULL
300	NULL
TTTTTTTTAC	NULL
CTCCACCGCC	NULL
TTCTAGTCTC	NULL
ACCGAAGGCT	NULL
TGTGGeCCATC	NULL
0	NULL
F_F_T	NULL
5	NULL
T	NULL
A	NULL
Fo*	NULL
s	NULL
H	NULL
R	NULL
R	NULL
IL	NULL
V	NULL
A	NULL
I	NULL
310	NULL
320	NULL
330	NULL
340	NULL
350	NULL
TCTGTAAAGT	NULL
TTCTGGGGAG	NULL
GTGGGCACGG	NULL
GGTAAACGCC	NULL
GGAGGGTTCT	NULL
0	NULL
§	NULL
V	NULL
K	NULL
F	NULL
L	NULL
G	NULL
R	NULL
Wo	NULL
A	NULL
R	NULL
G	NULL
K	NULL
R	NULL
R	NULL
R	NULL
V	NULL
I	NULL
360	NULL
370	NULL
3580	NULL
390	NULL
400	NULL
GTGGAGCCTA	NULL
TGGGACTGAC	NULL
TGGAGGCCAA	NULL
AGAACTTTGG	NULL
GCCGCAGATG	NULL
0	NULL
ow	NULL
§	NULL
L	NULL
-	NULL
W	NULL
D	NULL
*	NULL
Lo	NULL
E	NULL
A	NULL
Ko	NULL
E	NULL
Lo	NULL
W	NULL
A	NULL
A	NULL
D	NULL
Vv	NULL
-1	NULL
M	NULL
+1	NULL
M__G	NULL
L	NULL
T	NULL
G	NULL
6	NULL
g	NULL
R	NULL
T	NULL
L	NULL
G	NULL
R	NULL
RC	NULL
410	NULL
420	NULL
430	NULL
440	NULL
450	NULL
TACACCAGCG	NULL
TCACTCTTTT	NULL
GGTCTGTTAG	NULL
GGCCTTCATC	NULL
GCTCACATCA	NULL
0	NULL
Ho	NULL
Q	NULL
R	NULL
HS	NULL
F	NULL
G	NULL
L	NULL
L	NULL
G	NULL
P	NULL
S	NULL
S	NULL
Lo	NULL
T	NULL
S	NULL
-1	NULL
¥	NULL
T	NULL
s	NULL
Vv	NULL
T	NULL
L	NULL
L	NULL
v	NULL
_C	NULL
*	NULL
+1	NULL
T	NULL
_P	NULL
A	NULL
$	NULL
_	NULL
L	NULL
F	NULL
_W	NULL
5	NULL
V	NULL
R	NULL
A	NULL
F	NULL
_I	NULL
A	NULL
HI	NULL
R	NULL
460	NULL
470	NULL
_	NULL
&	NULL
-	NULL
ago	NULL
490	NULL
500	NULL
GGTTTCAGTG	NULL
TGAAACGGGA	NULL
AAACATAGCC	NULL
GCAATGGCTG	NULL
AAAATGGTGA	NULL
0	NULL
G	NULL
F	NULL
s	NULL
v	NULL
K	NULL
R	NULL
E	NULL
N	NULL
I	NULL
A	NULL
A	NULL
M	NULL
A	NULL
OE	NULL
N	NULL
G	NULL
D	NULL
+1	NULL
_C	NULL
E	NULL
T	NULL
G	NULL
K	NULL
H	NULL
S	NULL
R	NULL
N	NULL
G	NULL
*	NULL
*	NULL
0	NULL
*	NULL
510	NULL
520	NULL
530	NULL
540	NULL
550	NULL
TAATGAAAAG	NULL
ATGGCTGCCC	NULL
TGGAGGCCAA	NULL
AATCTGTCAT	NULL
CAAATTGAGT	NULL
0	NULL
N	NULL
E	NULL
K	NULL
M	NULL
A	NULL
A	NULL
L	NULL
E	NULL
A	NULL
K	NULL
I	NULL
C	NULL
H	NULL
q	NULL
I	NULL
E	NULL
Y	NULL
Figure	NULL
7	NULL
.	NULL

The	NULL
alternative	NULL
5°	NULL
terminus	NULL
contains	NULL
three	NULL
ATGs	NULL
.	NULL

All	NULL
the	NULL
hypothetical	NULL
reading	NULL
frames	NULL
starting	NULL
within	NULL
the	NULL
exon	NULL
1	NULL
'	NULL
are	NULL
italics	NULL
and	NULL
un-derlined	NULL
.	NULL

Stop	NULL
codons	NULL
are	NULL
indicated	NULL
by	NULL
(	NULL
*	NULL
)	NULL
.	NULL

Upstream	NULL
of	NULL
the	NULL
first	NULL
ATG	NULL
the	NULL
exon	NULL
1	NULL
'	NULL
sequence	NULL
contains	NULL
two	NULL
GC-rich	NULL
regions	NULL
(	NULL
underlined	NULL
)	NULL
.	NULL

The	NULL
first	NULL
reading	NULL
frame	NULL
contains	NULL
two	NULL
stop	NULL
codons	NULL
.	NULL

The	NULL
second	NULL
ATG	NULL
is	NULL
in	NULL
the	NULL
+1	NULL
frame	NULL
,	NULL
the	NULL
third	NULL
ATG	NULL
in	NULL
the	NULL
-1	NULL
frame	NULL
.	NULL

The	NULL
(	NULL
)	NULL
marks	NULL
the	NULL
splice	NULL
junction	NULL
2065	NULL
Troster	NULL
et	NULL
al	NULL
.	NULL

1	NULL
is	NULL
used	NULL
,	NULL
the	NULL
complete	NULL
intron	NULL
between	NULL
exon	NULL
1	NULL
and	NULL
exon	NULL
2	NULL
,	NULL
including	NULL
the	NULL
exon	NULL
1	NULL
'	NULL
sequence	NULL
locating	NULL
within	NULL
the	NULL
intron	NULL
,	NULL
is	NULL
removed	NULL
during	NULL
splicing	NULL
.	NULL

If	NULL
the	NULL
promotor	NULL
upstream	NULL
of	NULL
exon	NULL
1	NULL
'	NULL
but	NULL
downstream	NULL
of	NULL
the	NULL
exon	NULL
1	NULL
is	NULL
used	NULL
,	NULL
(	NULL
a	NULL
)	NULL
the	NULL
exon	NULL
1	NULL
is	NULL
not	NULL
transcribed	NULL
and	NULL
(	NULL
b	NULL
)	NULL
an	NULL
alternative	NULL
donor	NULL
splice	NULL
mRNA	NULL
site	NULL
within	NULL
the	NULL
intron	NULL
is	NULL
spliced	NULL
to	NULL
the	NULL
same	NULL
acceptor	NULL
splice	NULL
level	NULL
site	NULL
at	NULL
the	NULL
exon	NULL
2	NULL
.	NULL

Thereby	NULL
the	NULL
exon	NULL
1	NULL
is	NULL
replaced	NULL
by	NULL
the	NULL
exon	NULL
1	NULL
'	NULL
.	NULL

One	NULL
major	NULL
difference	NULL
between	NULL
the	NULL
two	NULL
types	NULL
of	NULL
La	NULL
mRNAs	NULL
is	NULL
based	NULL
on	NULL
the	NULL
fact	NULL
that	NULL
the	NULL
translation	NULL
initiation	NULL
site	NULL
of	NULL
the	NULL
exon	NULL
1	NULL
type	NULL
La	NULL
mRNA	NULL
locates	NULL
in	NULL
the	NULL
exon	NULL
2	NULL
,	NULL
since	NULL
the	NULL
exon	NULL
1	NULL
does	NULL
not	NULL
contain	NULL
an	NULL
ATG	NULL
sequence	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
exon	NULL
1	NULL
'	NULL
contains	NULL
three	NULL
further	NULL
ATGs	NULL
.	NULL

the	NULL
nuclear	NULL
antigen	NULL
La/SS-B	NULL
including	NULL
either	NULL
a	NULL
molecular	NULL
mimicry	NULL
with	NULL
(	NULL
retro	NULL
)	NULL
viral	NULL
epitopes	NULL
or	NULL
an	NULL
antigen	NULL
driven	NULL
mechanism	NULL
(	NULL
5	NULL
,	NULL
6	NULL
)	NULL
.	NULL

In	NULL
case	NULL
of	NULL
an	NULL
autoantigen	NULL
driven	NULL
mechanism	NULL
alterations	NULL
in	NULL
patients	NULL
with	NULL
respect	NULL
to	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
autoantigen	NULL
should	NULL
occur	NULL
.	NULL

However	NULL
,	NULL
such	NULL
pathophysiological	NULL
alterations	NULL
had	NULL
not	NULL
been	NULL
described	NULL
up	NULL
to	NULL
now	NULL
.	NULL

Therefore	NULL
we	NULL
started	NULL
to	NULL
analyze	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
La	NULL
gene	NULL
searching	NULL
for	NULL
alternative	NULL
transcripts	NULL
overexpressed	NULL
in	NULL
patients	NULL
.	NULL

For	NULL
that	NULL
purpose	NULL
a	NULL
cDNA	NULL
library	NULL
was	NULL
made	NULL
from	NULL
PBL	NULL
of	NULL
the	NULL
patient	NULL
(	NULL
Ma	NULL
;	NULL
8	NULL
)	NULL
with	NULL
pSS	NULL
and	NULL
the	NULL
library	NULL
was	NULL
screened	NULL
with	NULL
her	NULL
own	NULL
autoimmune	NULL
serum	NULL
.	NULL

Thereby	NULL
a	NULL
novel	NULL
form	NULL
of	NULL
La	NULL
mRNA	NULL
was	NULL
identified	NULL
.	NULL

The	NULL
two	NULL
isolated	NULL
alternative	NULL
La	NULL
cDNAs	NULL
differed	NULL
from	NULL
the	NULL
hitherto	NULL
known	NULL
La	NULL
cDNA	NULL
sequence	NULL
at	NULL
the	NULL
5¢	NULL
terminus	NULL
.	NULL

Both	NULL
alternative	NULL
La	NULL
cDNAs	NULL
started	NULL
with	NULL
an	NULL
unusual	NULL
5'-oligo	NULL
(	NULL
dT	NULL
)	NULL
-tail	NULL
and	NULL
lacked	NULL
the	NULL
exon	NULL
1	NULL
sequence	NULL
.	NULL

Instead	NULL
of	NULL
the	NULL
exon	NULL
1	NULL
an	NULL
alternative	NULL
5'-terminal	NULL
sequence	NULL
which	NULL
was	NULL
termed	NULL
as	NULL
exon	NULL
1	NULL
,	NULL
was	NULL
found	NULL
.	NULL

Using	NULL
the	NULL
technique	NULL
of	NULL
Southern	NULL
blotting	NULL
,	NULL
an	NULL
EcoRI	NULL
fragment	NULL
was	NULL
identified	NULL
to	NULL
contain	NULL
the	NULL
exon	NULL
1	NULL
'	NULL
in	NULL
healthy	NULL
donors	NULL
as	NULL
well	NULL
as	NULL
in	NULL
patients	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
concluded	NULL
that	NULL
the	NULL
exon	NULL
1	NULL
``	NULL
is	NULL
not	NULL
a	NULL
patient-specific	NULL
insert	NULL
.	NULL

The	NULL
4.8-kb	NULL
fragment	NULL
containing	NULL
the	NULL
exon	NULL
1	NULL
``	NULL
was	NULL
subcloned	NULL
from	NULL
a	NULL
genomic	NULL
A	NULL
clone	NULL
into	NULL
pBluescript	NULL
and	NULL
sequenced	NULL
.	NULL

Thereby	NULL
the	NULL
exon	NULL
1	NULL
'	NULL
including	NULL
its	NULL
oligo	NULL
(	NULL
dT	NULL
)	NULL
-tail	NULL
was	NULL
found	NULL
to	NULL
be	NULL
a	NULL
part	NULL
of	NULL
the	NULL
intron	NULL
between	NULL
exons	NULL
1	NULL
and	NULL
2	NULL
.	NULL

As	NULL
the	NULL
oligo	NULL
(	NULL
dT	NULL
)	NULL
was	NULL
also	NULL
found	NULL
within	NULL
the	NULL
genomic	NULL
sequence	NULL
,	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
oligo	NULL
(	NULL
dT	NULL
)	NULL
-tail	NULL
at	NULL
the	NULL
5	NULL
``	NULL
terminus	NULL
of	NULL
the	NULL
cDNAs	NULL
is	NULL
not	NULL
the	NULL
result	NULL
of	NULL
a	NULL
cloning	NULL
artifact	NULL
,	NULL
although	NULL
it	NULL
must	NULL
be	NULL
mentioned	NULL
that	NULL
the	NULL
length	NULL
found	NULL
for	NULL
the	NULL
genomic	NULL
oligo	NULL
(	NULL
dT	NULL
)	NULL
-tail	NULL
(	NULL
23	NULL
[	NULL
dTJ-residues	NULL
)	NULL
was	NULL
smaller	NULL
than	NULL
the	NULL
length	NULL
of	NULL
the	NULL
oligo	NULL
(	NULL
dT	NULL
)	NULL
-tails	NULL
of	NULL
the	NULL
cDNAs	NULL
(	NULL
31	NULL
[	NULL
dT	NULL
]	NULL
-residues	NULL
in	NULL
the	NULL
between	NULL
exon	NULL
1	NULL
'	NULL
and	NULL
exon	NULL
2	NULL
.	NULL

The	NULL
proposed	NULL
aa	NULL
sequence	NULL
of	NULL
the	NULL
La	NULL
protein	NULL
(	NULL
13	NULL
)	NULL
,	NULL
if	NULL
translation	NULL
starts	NULL
at	NULL
the	NULL
first	NULL
ATG	NULL
in	NULL
the	NULL
exon	NULL
2	NULL
(	NULL
bold	NULL
;	NULL
nt	NULL
484	NULL
)	NULL
.	NULL

(	NULL
4	NULL
)	NULL
70	NULL
80	NULL
90	NULL
100	NULL
110	NULL
La	NULL
acco	NULL
CC6camTcorce	NULL
agcore	NULL
--	NULL
sc	NULL
h	NULL
GCCeCCCTCGeseccecceceIrccICcC	NULL
CCCGCCGCCeCcICccéacccesce	NULL
2450	NULL
2460	NULL
2470	NULL
2480	NULL
2490	NULL
2500	NULL
120	NULL
130	NULL
140	NULL
150	NULL
160	NULL
170	NULL
o	NULL
CGCCGCCCGCGCCCCCTCGGCTCCGCCGCCTCCGSCTGCGSCCCACGCGSCGCTCGSCCT	NULL
pbb	NULL
air	NULL
bbb	NULL
ont	NULL
td	NULL
Ld	NULL
41	NULL
reacmh	NULL
CGCCGECCCCGCCGCCTCGec-CesCCTCraCcTec-AceAcCTessasccecasccecc	NULL
2510	NULL
2520	NULL
2530	NULL
2540	NULL
2550	NULL
2560	NULL
(	NULL
I1	NULL
)	NULL
20	NULL
30	NULL
40	NULL
50	NULL
60	NULL
70	NULL
La	NULL
GATGAGGGCAGCCACAGTCCCGTCTCTAAGGAACCGCGGAACTGCCTGGGCCACCAGCCA	NULL
HOL	NULL
OH	NULL
I	NULL
PDL	NULL
remc29	NULL
CGCCGCCAAG	NULL
GAAGCTCGCCACCTACCAAGCCTCCCGCCA	NULL
2460	NULL
2470	NULL
2480	NULL
2490	NULL
2500	NULL
2510	NULL
so	NULL
90	NULL
100	NULL
110	NULL
120	NULL
La	NULL
CGTeCeSes-	NULL
-	NULL
~	NULL
AACCCCAGGATCCCGCATIECCTCE	NULL
ascomcecceccecccs	NULL
Poa	NULL
ELA	NULL
bbb	NULL
a	NULL
boa	NULL
db	NULL
Got	NULL
a	NULL
HLL	NULL
remc29	NULL
GGAGGGGGGCCCCGCCGCCGCCTCCCG-ACCCGSCCCGCCGCCUTCéeseecceccecetc	NULL
2520	NULL
2530	NULL
2540	NULL
2550	NULL
2560	NULL
2570	NULL
130	NULL
140	NULL
150	NULL
160	NULL
170	NULL
180	NULL
La	NULL
CECCCCCTCGGCTCCGCCGCCTCCGSCTGCGGCCCACGCGGCGCTCGSCCTGAACGTGAG	NULL
remc29	NULL
CTCCCGC-CSSCCCCGCCGCCTCGSCCGSCCTCTACCTGCACGACc	NULL
caceecc	NULL
2580	NULL
2590	NULL
2600	NULL
2610	NULL
2620	NULL
2630	NULL
(	NULL
III	NULL
)	NULL
30	NULL
40	NULL
50	NULL
60	NULL
d	NULL
80	NULL
La	NULL
CAGTCCCGTCTCTAAGGAACCGCGGAACTGCCTGGGCCACCAGCCACGTGCGGGGAACCC	NULL
bbd	NULL
odb	NULL
ob	NULL
obb	NULL
bob	NULL
babi	NULL
d	NULL
hepvie	NULL
CCTCCTCCTCG	NULL
@	NULL
TCCTCGTCCTCCTCGTCCTCCTCGTCC-TCGTCCTCCTCCGAGGGAGAA	NULL
1430	NULL
1440	NULL
1450	NULL
1460	NULL
1470	NULL
1480	NULL
90	NULL
100	NULL
110	NULL
120	NULL
130	NULL
140	NULL
La	NULL
CAGGATCCCGCATICC-TCec	NULL
AGCCTCGCcsccecccececcccercescrccs	NULL
Ion	NULL
Poa	NULL
b	NULL
dota	NULL
perdi	NULL
abla	NULL
GH	NULL
ont	NULL
hepvie	NULL
GAAGACGAAGGAGTCCGGCCCGGCGCCCCACTCGCCCGCGéCCGescceccacceTercce	NULL
1490	NULL
1500	NULL
1510	NULL
1520	NULL
1530	NULL
1540	NULL
150	NULL
160	NULL
170	NULL
180	NULL
190	NULL
200	NULL
La	NULL
CCGCCTCCGSCTGCGSCCCACGCGGCGCTCGSCCTGAACGTGAGGAAGGCGAGGGGCGGA	NULL
Lb	NULL
rabt	NULL
Ob	NULL
beb	NULL
hepvie	NULL
CCGGCGCCCGCCGCGSCCC-CGCGSCCCTCGSCCTCCTCCGCCTCCGCCACCTCCTCCTC	NULL
1550	NULL
1560	NULL
1570	NULL
1580	NULL
1590	NULL
1600	NULL
Figure	NULL
8	NULL
.	NULL

-	NULL
Sequence	NULL
homologies	NULL
of	NULL
the	NULL
5'-end	NULL
upstream	NULL
of	NULL
the	NULL
oligo	NULL
(	NULL
dT	NULL
)	NULL
-tail	NULL
.	NULL

Comparisons	NULL
of	NULL
the	NULL
reversed	NULL
sequence	NULL
upstream	NULL
of	NULL
the	NULL
oligo	NULL
(	NULL
dT	NULL
)	NULL
-tail	NULL
with	NULL
the	NULL
EMBL	NULL
DNA	NULL
Data	NULL
Library	NULL
revealed	NULL
homologies	NULL
of	NULL
(	NULL
a	NULL
)	NULL
67.5	NULL
%	NULL
to	NULL
a	NULL
83	NULL
bp	NULL
overlap	NULL
within	NULL
the	NULL
v-myc	NULL
region	NULL
of	NULL
the	NULL
avian	NULL
myelocytomatosis	NULL
HBI	NULL
provirus	NULL
(	NULL
reacmh	NULL
;	NULL
EMBL	NULL
accession	NULL
number	NULL
M11784	NULL
)	NULL
;	NULL
(	NULL
b	NULL
)	NULL
60.8	NULL
%	NULL
homology	NULL
to	NULL
a	NULL
120	NULL
bp	NULL
overlap	NULL
encoding	NULL
for	NULL
the	NULL
gag-myc	NULL
fusion	NULL
protein	NULL
of	NULL
the	NULL
avian	NULL
myelocytomatosis	NULL
virus	NULL
of	NULL
the	NULL
same	NULL
region	NULL
(	NULL
remc	NULL
;	NULL
EMBL	NULL
accession	NULL
numbers	NULL
VO1174	NULL
and	NULL
JO2247	NULL
)	NULL
;	NULL
or	NULL
(	NULL
c	NULL
)	NULL
64	NULL
%	NULL
homology	NULL
to	NULL
a	NULL
125-bp	NULL
overlap	NULL
of	NULL
an	NULL
immediate-early	NULL
gene	NULL
of	NULL
pseudorabies	NULL
virus	NULL
(	NULL
kepvie	NULL
;	NULL
EMBL	NULL
accession	NULL
number	NULL
X15120	NULL
)	NULL
.	NULL

case	NULL
of	NULL
La19	NULL
and	NULL
52	NULL
in	NULL
the	NULL
case	NULL
of	NULL
La23	NULL
)	NULL
.	NULL

In	NULL
fact	NULL
these	NULL
differences	NULL
may	NULL
have	NULL
resulted	NULL
during	NULL
the	NULL
cloning	NULL
procedure	NULL
.	NULL

By	NULL
comparing	NULL
the	NULL
La	NULL
cDNA	NULL
sequences	NULL
with	NULL
the	NULL
genomic	NULL
sequence	NULL
all	NULL
the	NULL
used	NULL
splice	NULL
sites	NULL
became	NULL
evident	NULL
,	NULL
including	NULL
the	NULL
exon	NULL
1	NULL
intron	NULL
donor	NULL
splice	NULL
site	NULL
,	NULL
the	NULL
alternative	NULL
exon	NULL
1	NULL
'	NULL
intron	NULL
donor	NULL
splice	NULL
site	NULL
and	NULL
the	NULL
common	NULL
intron	NULL
exon	NULL
2	NULL
acceptor	NULL
splice	NULL
site	NULL
.	NULL

As	NULL
the	NULL
genomic	NULL
sequence	NULL
contains	NULL
a	NULL
1443-nt-long	NULL
intron	NULL
between	NULL
the	NULL
3'-end	NULL
of	NULL
the	NULL
exon	NULL
1	NULL
'	NULL
and	NULL
the	NULL
start	NULL
of	NULL
the	NULL
exon	NULL
2	NULL
,	NULL
which	NULL
is	NULL
absent	NULL
in	NULL
the	NULL
sequence	NULL
of	NULL
the	NULL
La	NULL
cDNAs	NULL
La19	NULL
and	NULL
La23	NULL
,	NULL
it	NULL
is	NULL
clear	NULL
that	NULL
these	NULL
La	NULL
cDNAs	NULL
2066	NULL
must	NULL
have	NULL
been	NULL
derived	NULL
from	NULL
alternatively	NULL
spliced	NULL
La	NULL
mRNAs	NULL
.	NULL

Using	NULL
the	NULL
5-RACE	NULL
technique	NULL
the	NULL
transcription	NULL
initiation	NULL
site	NULL
of	NULL
the	NULL
alternative	NULL
La	NULL
mRNA	NULL
was	NULL
determined	NULL
to	NULL
locate	NULL
68	NULL
nt	NULL
downstream	NULL
of	NULL
the	NULL
exon	NULL
1	NULL
donor	NULL
splice	NULL
site	NULL
.	NULL

According	NULL
to	NULL
this	NULL
result	NULL
,	NULL
the	NULL
transcription	NULL
of	NULL
the	NULL
alternative	NULL
La	NULL
mRNA	NULL
starts	NULL
within	NULL
the	NULL
intron	NULL
between	NULL
exon	NULL
1	NULL
and	NULL
exon	NULL
1	NULL
'	NULL
.	NULL

Therefore	NULL
,	NULL
an	NULL
alternative	NULL
promotor	NULL
might	NULL
locate	NULL
upstream	NULL
of	NULL
this	NULL
alternative	NULL
transcription	NULL
initiation	NULL
site	NULL
.	NULL

Indeed	NULL
,	NULL
searching	NULL
for	NULL
putative	NULL
transcription	NULL
factor	NULL
binding	NULL
sites	NULL
resulted	NULL
in	NULL
the	NULL
identification	NULL
of	NULL
a	NULL
putative	NULL
TFIID	NULL
binding	NULL
site	NULL
at	NULL
the	NULL
expected	NULL
position	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

It	NULL
is	NULL
interesting	NULL
to	NULL
note	NULL
that	NULL
in	NULL
addition	NULL
to	NULL
the	NULL
TFIID	NULL
binding	NULL
site	NULL
a	NULL
series	NULL
of	NULL
further	NULL
consensus	NULL
sequences	NULL
for	NULL
other	NULL
transcription	NULL
factors	NULL
,	NULL
which	NULL
could	NULL
be	NULL
involved	NULL
in	NULL
regulation	NULL
of	NULL
a	NULL
differential	NULL
expression	NULL
of	NULL
the	NULL
two	NULL
types	NULL
of	NULL
La	NULL
mRNAs	NULL
,	NULL
exists	NULL
in	NULL
the	NULL
intron	NULL
downstream	NULL
of	NULL
the	NULL
exon	NULL
1	NULL
as	NULL
summarized	NULL
in	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

These	NULL
transcription	NULL
factor	NULL
binding	NULL
sites	NULL
include	NULL
common	NULL
transcription	NULL
factors	NULL
such	NULL
as	NULL
SP1	NULL
but	NULL
also	NULL
of	NULL
the	NULL
AP1	NULL
and	NULL
AP2	NULL
family	NULL
.	NULL

Of	NULL
most	NULL
interest	NULL
is	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
NF-KB	NULL
element	NULL
218	NULL
nt	NULL
downstream	NULL
of	NULL
the	NULL
exon	NULL
1	NULL
,	NULL
as	NULL
NF-KB	NULL
is	NULL
known	NULL
to	NULL
be	NULL
activated	NULL
by	NULL
UV	NULL
irradi-ation	NULL
,	NULL
dsRNA	NULL
,	NULL
acute	NULL
phase	NULL
proteins	NULL
,	NULL
including	NULL
some	NULL
inter-leukins	NULL
,	NULL
interferons	NULL
,	NULL
tumor	NULL
necrosis	NULL
factor	NULL
,	NULL
and	NULL
retroviruses	NULL
(	NULL
26	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
NF-	NULL
«	NULL
B	NULL
elements	NULL
also	NULL
exist	NULL
in	NULL
retroviruses	NULL
and	NULL
are	NULL
assumed	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
activation	NULL
of	NULL
retroviruses	NULL
,	NULL
viral	NULL
latency	NULL
,	NULL
and	NULL
development	NULL
of	NULL
autoimmunity	NULL
.	NULL

The	NULL
NF-	NULL
«	NULL
B	NULL
element	NULL
in	NULL
the	NULL
La	NULL
gene	NULL
(	NULL
5-GGGGTTCCCC	NULL
)	NULL
is	NULL
very	NULL
similar	NULL
to	NULL
the	NULL
NF-KB	NULL
binding	NULL
site	NULL
in	NULL
the	NULL
HIV	NULL
virus	NULL
(	NULL
5-GGGGAT	NULL
TCCCC	NULL
)	NULL
,	NULL
which	NULL
has	NULL
been	NULL
described	NULL
to	NULL
cause	NULL
symptoms	NULL
similar	NULL
to	NULL
pSS	NULL
(	NULL
4	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
the	NULL
conditions	NULL
known	NULL
to	NULL
activate	NULL
NF-	NULL
«	NULL
B	NULL
are	NULL
the	NULL
conditions	NULL
known	NULL
to	NULL
cause	NULL
and	NULL
induce	NULL
acute	NULL
disease	NULL
in	NULL
SLE	NULL
patients	NULL
.	NULL

Therefore	NULL
,	NULL
it	NULL
is	NULL
tempting	NULL
to	NULL
speculate	NULL
that	NULL
here	NULL
could	NULL
be	NULL
a	NULL
first	NULL
hint	NULL
for	NULL
a	NULL
link	NULL
between	NULL
the	NULL
development	NULL
of	NULL
disease	NULL
as	NULL
well	NULL
as	NULL
inducers	NULL
of	NULL
acute	NULL
disease	NULL
and	NULL
an	NULL
alternative	NULL
expression	NULL
of	NULL
the	NULL
gene	NULL
encoding	NULL
for	NULL
the	NULL
autoantigen	NULL
La/SS-B	NULL
.	NULL

In	NULL
summary	NULL
our	NULL
genomic	NULL
data	NULL
show	NULL
that	NULL
the	NULL
mechanism	NULL
leading	NULL
to	NULL
the	NULL
alternative	NULL
form	NULL
of	NULL
La	NULL
mRNA	NULL
includes	NULL
a	NULL
promotor	NULL
switching	NULL
and	NULL
an	NULL
alternative	NULL
splicing	NULL
event	NULL
.	NULL

At	NULL
present	NULL
the	NULL
function	NULL
of	NULL
the	NULL
alternative	NULL
La	NULL
mRNA	NULL
remains	NULL
obscure	NULL
,	NULL
as	NULL
the	NULL
complete	NULL
exon	NULL
1	NULL
'	NULL
as	NULL
determined	NULL
with	NULL
the	NULL
5'-RACE	NULL
experiment	NULL
does	NULL
not	NULL
only	NULL
contain	NULL
the	NULL
unusual	NULL
oligo	NULL
(	NULL
dT	NULL
)	NULL
-tail	NULL
,	NULL
but	NULL
also	NULL
two	NULL
GC-rich	NULL
regions	NULL
and	NULL
three	NULL
ATGs	NULL
.	NULL

However	NULL
,	NULL
there	NULL
are	NULL
two	NULL
stop	NULL
codons	NULL
in	NULL
the	NULL
reading	NULL
frame	NULL
of	NULL
the	NULL
first	NULL
ATG	NULL
.	NULL

Moreover	NULL
,	NULL
the	NULL
second	NULL
and	NULL
the	NULL
third	NULL
ATG	NULL
are	NULL
not	NULL
in	NULL
the	NULL
correct	NULL
reading	NULL
frame	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

Similar	NULL
looking	NULL
alternative	NULL
transcripts	NULL
had	NULL
been	NULL
described	NULL
for	NULL
other	NULL
housekeeping	NULL
proteins	NULL
.	NULL

In	NULL
these	NULL
cases	NULL
it	NULL
had	NULL
been	NULL
suggested	NULL
that	NULL
the	NULL
alternative	NULL
transcripts	NULL
either	NULL
are	NULL
not	NULL
translated	NULL
into	NULL
protein	NULL
but	NULL
should	NULL
throttle	NULL
the	NULL
translation	NULL
or	NULL
represent	NULL
stored	NULL
intermediates	NULL
for	NULL
a	NULL
further	NULL
tissue-dependent	NULL
5'-terminal	NULL
processing	NULL
(	NULL
18	NULL
)	NULL
.	NULL

By	NULL
consequence	NULL
,	NULL
future	NULL
studies	NULL
are	NULL
required	NULL
to	NULL
clarify	NULL
the	NULL
physiological	NULL
function	NULL
of	NULL
the	NULL
alternative	NULL
La	NULL
mRNA	NULL
.	NULL

Moreover	NULL
,	NULL
the	NULL
behavior	NULL
under	NULL
pathophysiological	NULL
conditions	NULL
must	NULL
be	NULL
elucidated	NULL
.	NULL

For	NULL
example	NULL
it	NULL
is	NULL
well	NULL
established	NULL
that	NULL
active	NULL
retroviruses	NULL
take	NULL
use	NULL
of	NULL
read	NULL
through	NULL
of	NULL
stop	NULL
codons	NULL
and	NULL
ribosomal	NULL
frame	NULL
shiftings	NULL
during	NULL
translation	NULL
of	NULL
their	NULL
proteins	NULL
.	NULL

Alternative	NULL
Transcript	NULL
Encoding	NULL
for	NULL
the	NULL
Autoantigen	NULL
La/SS-B	NULL
So	NULL
it	NULL
is	NULL
tempting	NULL
to	NULL
speculate	NULL
that	NULL
similar	NULL
events	NULL
could	NULL
occur	NULL
during	NULL
translation	NULL
of	NULL
the	NULL
alternative	NULL
La	NULL
mRNA	NULL
in	NULL
retroviral	NULL
infected	NULL
cells	NULL
leading	NULL
to	NULL
NH	NULL
;	NULL
terminally	NULL
altered	NULL
La	NULL
proteins	NULL
,	NULL
which	NULL
could	NULL
finally	NULL
induce	NULL
the	NULL
autoimmune	NULL
reactions	NULL
against	NULL
the	NULL
La	NULL
protein	NULL
.	NULL

We	NULL
thank	NULL
Dr.	NULL
Kenan	NULL
and	NULL
Dr.	NULL
Keene	NULL
(	NULL
Duke	NULL
University	NULL
,	NULL
Durham	NULL
,	NULL
NC	NULL
)	NULL
for	NULL
providing	NULL
us	NULL
with	NULL
the	NULL
charon	NULL
phage	NULL
ALa2-1	NULL
and	NULL
Dr.	NULL
Mayet	NULL
(	NULL
I.	NULL
Med	NULL
.	NULL

Universitit	NULL
,	NULL
Mainz	NULL
,	NULL
Germany	NULL
)	NULL
for	NULL
the	NULL
blood	NULL
sample	NULL
of	NULL
the	NULL
patient	NULL
(	NULL
Ma	NULL
)	NULL
.	NULL

This	NULL
investigation	NULL
was	NULL
supported	NULL
by	NULL
a	NULL
grant	NULL
from	NULL
the	NULL
Deutsche	NULL
Forschungsgemeinschaft	NULL
(	NULL
Ba1145/	NULL
1-2	NULL
)	NULL
.	NULL

M.	NULL
Bachmann	NULL
is	NULL
a	NULL
recipient	NULL
of	NULL
a	NULL
C3	NULL
Hermann-and-Lilly	NULL
Schilling	NULL
professorship	NULL
granted	NULL
by	NULL
the	NULL
``	NULL
Stifterver-band	NULL
fiir	NULL
die	NULL
Deutsche	NULL
Wissenschaft	NULL
.	NULL
``	NULL

I.	NULL
Semsei	NULL
is	NULL
a	NULL
recipient	NULL
of	NULL
a	NULL
fellowship	NULL
donated	NULL
by	NULL
Alexander	NULL
von	NULL
Humboldt-Stiftung	NULL
.	NULL

Address	NULL
correspondence	NULL
to	NULL
Dr.	NULL
Michael	NULL
Bachmann	NULL
,	NULL
Institut	NULL
fiir	NULL
Physiologische	NULL
Chemie	NULL
,	NULL
Johannes-Gutenberg	NULL
Universitit	NULL
,	NULL
Duesbergweg	NULL
6	NULL
,	NULL
55099	NULL
Mainz	NULL
,	NULL
Germany	NULL
.	NULL

Received	NULL
for	NULL
publication	NULL
26	NULL
May	NULL
1994	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
16	NULL
August	NULL
1994	NULL
.	NULL

References	NULL
1	NULL
.	NULL

10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

Fox	NULL
,	NULL
RI	NULL
.	NULL

,	NULL
M.	NULL
Luppi	NULL
,	NULL
P.	NULL
Pisa	NULL
,	NULL
and	NULL
H.-L.	NULL
Kang	NULL
.	NULL

1992	NULL
.	NULL

Potential	NULL
role	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
in	NULL
Sjégren	NULL
's	NULL
syndrome	NULL
and	NULL
rheuma-toid	NULL
arthritis	NULL
.	NULL

J.	NULL
Rheumatol	NULL
.	NULL

19:18.	NULL
.	NULL

Talal	NULL
,	NULL
N.	NULL
,	NULL
M.J.	NULL
Dauphinee	NULL
,	NULL
H.	NULL
Dang	NULL
,	NULL
S.S.	NULL
Alexander	NULL
,	NULL
DJ	NULL
.	NULL

Hart	NULL
,	NULL
and	NULL
R.F	NULL
.	NULL

Garry	NULL
.	NULL

1990	NULL
.	NULL

Detection	NULL
of	NULL
serum	NULL
antibodies	NULL
to	NULL
retroviral	NULL
proteins	NULL
in	NULL
patients	NULL
with	NULL
primary	NULL
Sjdgrens	NULL
syndrome	NULL
(	NULL
autoimmune	NULL
exocrinopathy	NULL
)	NULL
.	NULL

Arthritis	NULL
Rheum	NULL
.	NULL

33:774.	NULL
.	NULL

Moutsopoulos	NULL
,	NULL
H.M.	NULL
,	NULL
and	NULL
P.	NULL
Youinou	NULL
.	NULL

1991	NULL
.	NULL

New	NULL
develop	NULL
ments	NULL
in	NULL
Sjogren	NULL
's	NULL
syndrome	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Rheumatol	NULL
.	NULL

3:815.	NULL
.	NULL

Talal	NULL
,	NULL
N.	NULL
1991	NULL
.	NULL

AIDS	NULL
and	NULL
Sjogren	NULL
's	NULL
syndrome	NULL
.	NULL

Bull	NULL
.	NULL

Rheum	NULL
.	NULL

Dis	NULL
.	NULL

40:6.	NULL
.	NULL

Meilof	NULL
,	NULL
J.F	NULL
.	NULL

,	NULL
K.M	NULL
.	NULL

Hebeda	NULL
,	NULL
J.	NULL
de-Jong	NULL
,	NULL
and	NULL
R.J.	NULL
Smeenk	NULL
.	NULL

1992	NULL
.	NULL

Analysis	NULL
of	NULL
heavy	NULL
and	NULL
light	NULL
chain	NULL
use	NULL
of	NULL
lupus-associated	NULL
anti-La/SS-B	NULL
and	NULL
anti-Sm	NULL
autoantibodies	NULL
reveals	NULL
two	NULL
distinct	NULL
underlying	NULL
immunoregulatory	NULL
mechanisms	NULL
.	NULL

Res	NULL
.	NULL

Immunol	NULL
.	NULL

143:711.	NULL
.	NULL

McNeilage	NULL
,	NULL
LJ	NULL
.	NULL

,	NULL
K.	NULL
Umapathysivam	NULL
,	NULL
E.	NULL
Macmillan	NULL
,	NULL
A.	NULL
Guidolin	NULL
,	NULL
S.	NULL
Whittingham	NULL
,	NULL
and	NULL
T.	NULL
Gordon	NULL
.	NULL

1992	NULL
.	NULL

Definition	NULL
of	NULL
a	NULL
discontinuous	NULL
immunodominant	NULL
epitope	NULL
at	NULL
the	NULL
NH	NULL
;	NULL
terminus	NULL
of	NULL
the	NULL
La/SS-B	NULL
ribonucleoprotein	NULL
autoantigen	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

89:1652.	NULL
.	NULL

Tan	NULL
,	NULL
E.M.	NULL
1989	NULL
.	NULL

Antinuclear	NULL
antibodies	NULL
:	NULL
diagnostic	NULL
markers	NULL
for	NULL
autoimmune	NULL
diseases	NULL
and	NULL
probes	NULL
for	NULL
cell	NULL
biology	NULL
.	NULL

Adv	NULL
.	NULL

Immunol	NULL
.	NULL

44:93.	NULL
.	NULL

Bachmann	NULL
,	NULL
M.	NULL
,	NULL
K.	NULL
Pfeifer	NULL
,	NULL
H.C.	NULL
Schroder	NULL
,	NULL
and	NULL
W.E.G	NULL
.	NULL

Miller	NULL
.	NULL

1990	NULL
.	NULL

Characterization	NULL
of	NULL
the	NULL
autoantigen	NULL
La	NULL
as	NULL
a	NULL
nucleic	NULL
acid	NULL
dependent	NULL
ATPase/dATPase	NULL
with	NULL
melting	NULL
properties	NULL
.	NULL

Cell	NULL
.	NULL

60:85.	NULL
.	NULL

Gottlieb	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
J.A	NULL
.	NULL

Steitz	NULL
.	NULL

1989	NULL
.	NULL

Function	NULL
of	NULL
the	NULL
mammalian	NULL
La	NULL
protein	NULL
:	NULL
evidence	NULL
for	NULL
its	NULL
activity	NULL
in	NULL
transcription	NULL
termination	NULL
by	NULL
RNA	NULL
polymerase	NULL
III	NULL
.	NULL

EMBO	NULL
(	NULL
Eur	NULL
.	NULL

Mol	NULL
.	NULL

Biol	NULL
.	NULL

Organ	NULL
.	NULL
)	NULL

.	NULL

8:851	NULL
.	NULL

.1	NULL
]	NULL
\/Ieerovitch	NULL
,	NULL
K.	NULL
,	NULL
VV	NULL
.	NULL

Svitkin	NULL
,	NULL
H.S	NULL
.	NULL

Lee	NULL
,	NULL
F.	NULL
Leibkowicz	NULL
,	NULL
D.	NULL
Kenan	NULL
,	NULL
EK.L	NULL
.	NULL

Chan	NULL
,	NULL
V.I	NULL
.	NULL

Agol	NULL
,	NULL
J.D	NULL
.	NULL

Keene	NULL
,	NULL
and	NULL
N.J.	NULL
Sonen-berg	NULL
.	NULL

1993	NULL
.	NULL

La	NULL
autoantigen	NULL
enhances	NULL
and	NULL
corrects	NULL
aberrant	NULL
translation	NULL
of	NULL
poliovirus	NULL
RNA	NULL
in	NULL
reticulo	NULL
lysate	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

67:3798	NULL
.	NULL

Chambers	NULL
,	NULL
J.C.	NULL
,	NULL
and	NULL
J.D	NULL
.	NULL

Keene	NULL
.	NULL

1985	NULL
.	NULL

Isolation	NULL
and	NULL
analysis	NULL
of	NULL
cDNA	NULL
clones	NULL
expressing	NULL
the	NULL
human	NULL
lupus	NULL
La	NULL
antigen	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

82:2115	NULL
.	NULL

Rauh	NULL
,	NULL
A.J.G	NULL
.	NULL

,	NULL
H.	NULL
Hornig	NULL
,	NULL
and	NULL
R.	NULL
Lihrmann	NULL
.	NULL

1988	NULL
.	NULL

At	NULL
least	NULL
three	NULL
distinct	NULL
B	NULL
cell	NULL
epitopes	NULL
reside	NULL
in	NULL
the	NULL
C-terminal	NULL
half	NULL
of	NULL
La	NULL
protein	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
a	NULL
recombinant	NULL
DNA	NULL
approach	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

18:2049	NULL
.	NULL

2067	NULL
Troster	NULL
et	NULL
al	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

Chan	NULL
,	NULL
EK.L	NULL
.	NULL

,	NULL
K.F	NULL
.	NULL

Sullivan	NULL
,	NULL
and	NULL
E.M.	NULL
Tan	NULL
.	NULL

1989	NULL
.	NULL

Ribonucleoprotein	NULL
SS-B/La	NULL
belongs	NULL
to	NULL
a	NULL
protein	NULL
family	NULL
with	NULL
consensus	NULL
sequences	NULL
for	NULL
RNA-binding	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

17:2233	NULL
.	NULL

Sturgess	NULL
,	NULL
A.D.	NULL
,	NULL
M.G	NULL
.	NULL

Peterson	NULL
,	NULL
LJ	NULL
.	NULL

McNeilage	NULL
,	NULL
S.	NULL
Wittingham	NULL
,	NULL
and	NULL
R.L	NULL
.	NULL

Coppel	NULL
.	NULL

1988	NULL
.	NULL

Characteristics	NULL
and	NULL
epitope	NULL
mapping	NULL
of	NULL
a	NULL
cloned	NULL
human	NULL
autoantigen	NULL
La	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

140:3212	NULL
.	NULL

Kohsaka	NULL
,	NULL
H.	NULL
,	NULL
K.	NULL
Yamamoto	NULL
,	NULL
H.	NULL
Fujii	NULL
,	NULL
H.	NULL
Miura	NULL
,	NULL
and	NULL
N.	NULL
Miyasaka	NULL
.	NULL

1990	NULL
.	NULL

Fine	NULL
epitope	NULL
mapping	NULL
of	NULL
the	NULL
human	NULL
SS-B/La	NULL
protein	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
distinct	NULL
autoepitope	NULL
homologous	NULL
to	NULL
a	NULL
viral	NULL
Gag	NULL
polyprotein	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

85:1566	NULL
.	NULL

Pruijn	NULL
,	NULL
G.J.M	NULL
.	NULL

,	NULL
RL	NULL
.	NULL

Slobbe	NULL
,	NULL
and	NULL
WJ	NULL
.	NULL

van	NULL
Venrooij	NULL
.	NULL

1991	NULL
.	NULL

Analysis	NULL
of	NULL
protein-RNA	NULL
interactions	NULL
within	NULL
Ro	NULL
ribonucleoprotein	NULL
complexes	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

19:5173	NULL
.	NULL

Chambers	NULL
,	NULL
J.C.	NULL
,	NULL
D.	NULL
Kenan	NULL
,	NULL
B.J	NULL
.	NULL

Martin	NULL
,	NULL
and	NULL
J.D	NULL
.	NULL

Keene	NULL
.	NULL

1988	NULL
.	NULL

Genomic	NULL
structure	NULL
and	NULL
amino	NULL
acid	NULL
sequence	NULL
domains	NULL
of	NULL
human	NULL
La	NULL
autoantigen	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

263:18043	NULL
.	NULL

Kozak	NULL
,	NULL
M.	NULL
1991	NULL
.	NULL

An	NULL
analysis	NULL
of	NULL
vertebrate	NULL
mRNA	NULL
sequences	NULL
:	NULL
intimations	NULL
of	NULL
translational	NULL
control	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

115:887	NULL
.	NULL

Chirgwin	NULL
,	NULL
J.	NULL
,	NULL
A.	NULL
Przybyla	NULL
,	NULL
R.	NULL
McDonald	NULL
,	NULL
and	NULL
W.	NULL
Rutter	NULL
.	NULL

1979	NULL
.	NULL

Isolation	NULL
of	NULL
biologically	NULL
active	NULL
ribonucleic	NULL
acid	NULL
from	NULL
sources	NULL
enriced	NULL
in	NULL
ribonuclease	NULL
.	NULL

Biochemistry	NULL
.	NULL

18:5294	NULL
.	NULL

Semsel	NULL
,	NULL
I.	NULL
,	NULL
S.	NULL
Ma	NULL
,	NULL
and	NULL
R.G	NULL
.	NULL

Cutler	NULL
,	NULL
1989	NULL
,	NULL
Tissue	NULL
and	NULL
age	NULL
specific	NULL
expression	NULL
of	NULL
the	NULL
mye	NULL
proto-oncogene	NULL
family	NULL
throughout	NULL
the	NULL
life	NULL
span	NULL
of	NULL
C57BL/6J	NULL
mouse	NULL
strain	NULL
.	NULL

Oncogene	NULL
.	NULL

4:465	NULL
.	NULL

Short	NULL
,	NULL
J.M	NULL
.	NULL

,	NULL
J.M	NULL
.	NULL

Fernandez	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Sorge	NULL
,	NULL
and	NULL
W.	NULL
Huse	NULL
.	NULL

1988	NULL
.	NULL

Lambda	NULL
ZAP	NULL
:	NULL
a	NULL
bacteriophage	NULL
Lambda	NULL
expression	NULL
vector	NULL
with	NULL
in	NULL
vivo	NULL
excision	NULL
properties	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

16:7583	NULL
.	NULL

Mierendorf	NULL
,	NULL
R.C	NULL
.	NULL

,	NULL
C.	NULL
Percy	NULL
,	NULL
and	NULL
R.A.	NULL
Young	NULL
.	NULL

1987	NULL
.	NULL

Gene	NULL
isolation	NULL
by	NULL
screening	NULL
Lambda	NULL
gt11	NULL
libraries	NULL
with	NULL
antibodies	NULL
.	NULL

Methods	NULL
Enzymol	NULL
.	NULL

152:458	NULL
.	NULL

Sambrook	NULL
,	NULL
J.	NULL
,	NULL
E.F.	NULL
Fritsch	NULL
,	NULL
and	NULL
T.	NULL
Maniatis	NULL
.	NULL

1989	NULL
.	NULL

Molecular	NULL
Cloning	NULL
:	NULL
A	NULL
Laboratory	NULL
Manual	NULL
.	NULL

Cold	NULL
Spring	NULL
Harbor	NULL
Press	NULL
,	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
,	NULL
NY	NULL
.	NULL

1:25	NULL
;	NULL
11:59	NULL
;	NULL
IX:44	NULL
.	NULL

Holmes	NULL
,	NULL
D.S	NULL
.	NULL

,	NULL
and	NULL
B.	NULL
Quigley	NULL
.	NULL

1981	NULL
.	NULL

A	NULL
rapid	NULL
boiling	NULL
method	NULL
for	NULL
the	NULL
preparation	NULL
of	NULL
bacterial	NULL
plasmids	NULL
.	NULL

Anal	NULL
.	NULL

Biochem	NULL
.	NULL

114:193	NULL
.	NULL

Henikoff	NULL
,	NULL
S.	NULL
1987	NULL
.	NULL

Unidirectional	NULL
digestion	NULL
with	NULL
exonuclease	NULL
III	NULL
in	NULL
DNA	NULL
sequence	NULL
analysis	NULL
.	NULL

Methods	NULL
Enzymol	NULL
.	NULL

11:156	NULL
.	NULL

Schreck	NULL
,	NULL
R.	NULL
,	NULL
K.	NULL
Albermann	NULL
,	NULL
and	NULL
P.A	NULL
.	NULL

Baeuerle	NULL
.	NULL

1992	NULL
.	NULL

Nuclear	NULL
factor	NULL
kappa	NULL
B	NULL
:	NULL
an	NULL
oxidative	NULL
stress-responsive	NULL
transcription	NULL
factor	NULL
of	NULL
eukarytic	NULL
cells	NULL
(	NULL
a	NULL
review	NULL
)	NULL
.	NULL

Free	NULL
Radical	NULL
Research	NULL
Communica-tions	NULL
.	NULL

17:221	NULL
.	NULL

